Библиография. «Ваша жизнь в ваших руках. Как понять, победить и предотвратить рак груди и яичников»

Предисловие к четвертому изданию

1. Plant, Jane and Tidey, Gill, 2002. The Plant Programme. Paperback edition. Virgin Books; Plant, Jane and Tidey, Gill, 2005. Eating for Better Health. Virgin Books.

2. Kradjian, Robert D., 1994. Save Yourself from Breast Cancer. Berkley Publishing.

3. Plant, Jane and Tidey, Gill, 2003. Understanding, Preventing and Overcoming Osteoporosis. Virgin Books.

Добро пожаловать

1. Selected causes of death: by gender and age. Office for National Statistics; General Register Office for Scotland; Northern Ireland Statistics and Research Agency. 1997.

2. Deaths: selected causes (International Classification) and sex, 1971 onwards (England and Wales): Health Statistics Quarterly, 04.1998

3. http://who-pcc.iarc.fr/

4. Trichopoulos, Dimitrios, Li, Frederick, P., and Hunter, David J, 1996. What Causes Cancer? Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 80–85.

Глава 1

1. Plant, Jane A. and Moore, P. J., 1979. Geochemical mapping and interpretation in Britain. Phil. Trans. Roy. SocLondon, B288, pp. 95-112.

2. Plant, Jane A., Smith, D., Smith, B. and Williams, L., 2000. Environmental Geochemistry at the Global Scale. Geological Society Special Issue.

3. Dewey, John E, 1999. Geoscientist 9, 6 June, Society Awards, pp. 2–4.

4. Blair’s war on cancer is a sham, say top doctors. Independent On Sunday. 14 November 1999.

5. Rennie, J, and Rusting, R., 1996. Making Headway Against Cancer. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 56-9.

6. Peto, R. and others, 2000. Smoking, Smoking Cessation and Lung Cancer in the UK since 1950. British Medical Journal, 321, 323-9.

7. Raleigh, V. S., 1999. World Population and Health in Transition. British Medical Journal, 319, 981–984.

8. Packham, D.E., 1999. Impacts of Commercialisation and Privatisation on Capabilities for Scientific Advice, Oracles or Scapegoats? IPMS Conference notes, October.

See also: Packham, David and Tasker, Mary, 1997. Industry and the academy – a Faustian contract. Industry and Higher Education, April, 85–90.

9. World Health Organization’s International Agency for Research on Cancer website: http://who-pcc.iarc.fr/

10. Physicians Committee for Responsible Medicine: PCRM Update of Winter 1991.

11. Cancer Research Campaign Factsheet 6.2, 1996.

12. Депрессия – очень распространенное явление: за год о симптомах депрессии сообщают более двух миллионов человек. Если вы страдаете депрессией, постарайтесь разобраться, не вызвана ли она реальными проблемами? В этом случае обратитесь за практической помощью и советом. Гражданское консультационное бюро предоставляет бесплатные советы по финансовым и юридическим вопросам, а «Самаритяне» или ваши друзья помогут разобраться с эмоциональными трудностями и научить с ними справляться. Хорошие советы нередко дает MIND, благотворительная организация, занимающаяся душевным здоровьем. В одной из ее недавних брошюр о депрессии (MIND 1999. Depression – don’t let it get you down. MIND and Pharmacy Healthcare; Mind Information, 15–19 Broadway, London El5 4BQ; Pharmacy Healthcare scheme, 1 Lambeth High Street, London SEI 7JN) утверждается, что «таблетки для симптомов, а разговор – для решения проблем». Вы должны питаться качественной, разнообразной пищей, поскольку в ней нуждается мозг, не употреблять искусственные органофосфаты (см. главу 6) и алкоголь в больших количествах. Если у вас серьезная депрессия, обратитесь за медицинской помощью. Хотя у современных антидепрессантов есть побочные эффекты, лучше иметь их, чем страдать от тяжелой депрессии.

13. The Times, 7 February 1998.

14. Сох, Peter and Brusseau, Peggy, 1992. Superliving: A Beginner's Guide to Medspeak, Vermillion.

15. Boots the Chemist, 1998. Breast Awareness – an essential guide. Be enlightened, not frightened. Published in association with the charity Breast Cancer Care.

16. Sunday Correspondent, 26 November 1989.

17. Alternative Therapy, British Medical Association, 1986.

18. New Scientist, 27 August 1987.

19. Vickers, A. and Zollman, C., 1999. ABC of complementary medicine: Acupuncture. British Medical Journal, 9 October, 973–976.

20. Gerson, M., 1958. A Cancer Therapy: Results of Fifty Cases, Gerson Institute, California.

Forbes, Alec, 1984. The Bristol Diet, Century.

21. Greenwald, P., 1996. Chemoprevention of Cancer. Scientific American, Special issue: What you need to know about Cancer, vol. 275, 3, pp. 96-100; and see also the World Health Organisation’s International Agency for Research on Cancer website; http://who-pcc.iarc.fr/ and see also the British National Formulary, 1998.

22. Section on cytotoxic (cell poisoning) drugs in the British National Formularv, 1998.

Глава 2

1. Weinberg, Robert A., 1996. How Cancer Arises. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 62–70.

2. Pollack, M.N. and others, 1998. IGF-1 Risk Factor for Prostate Cancer. Science, 279, 563–566.

Pollack, M.N., Huynh, H.T., and Lefebvre, S.P., 1992. Tamoxifen reduces serum insulin-like growth factor 1 (IGF-1). Br Cancer Res Treat, 22, 91-100.

Pollack, M.N., Polychronakos, C., Yousefi, S., and Richard, M., 1988. Characterisation of insulin-like growth factor-1 (IGF-1) receptors of human breast cancer cells. Biochem Biophy Res Commun, 154, 1, 326–331.

3. Oliff, Alien, Gibbs, Jackson, B. and McCormick, Frank, 1996. New Molecular Targets for Cancer Therapy. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 144–149.

4. Weinberg, Robert A., 1996, How Cancer Arises. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 62–70.

5. Jain, R. K., 1994. Barriers to Drug Delivery in Solid Tumours. Scientific American, July, 271 (1), pp. 58–65.

Глава 3

1. Trichopoulos, Dimitros, Li, Frederick, V. and Hunter, David J., 1996. What Causes Cancer? Scientific American, Special Issue, What you need to know about Cancer. September 275, 3, 80–85.

2. Boots the Chemist, 1998. Breast Awareness – an essential guide, Be enlightened, not frightened. Published in association with the charity Breast Cancer Care.

3. Trichopoulos, Dimitrios, Li, Frederick, P. and Hunter, David J., 1996. What Causes Cancer Scientific American, Special Issue, What you need to know about Cancer. September, 275, 3, 80–85.

4. Holland, J.C., 1996. Cancer’s Psychological Challenges. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 158–161.

5. http://www.who.int/nut/malnutrition_worldwide.htm

6. Cancer Incidence in Five Continents, 1997. Vol VII, published by the IARC (International Agency for Research on Cancer).

7. Cancer Incidence in Five Continents. 1997. Vol. VII, published by the IARC (International Agency for Research on Cancer).

8. Kliewer, E.V. and Smith, K.R., 1995. Breast cancer mortality among immigrants in Australia and Canada. Journal of Natl Cancer Institute, 87, 15, 1154–1161. See also Cancer Research Campaign, 1996, Factsheet 6.2, Breast Cancer – UK.

9. Campbell, Т. C. and Junshi, C., 1994. Diet and chronic degenerative disease perspectives from China. Am. J Clin. Nutr, 59, Suppl., 11 535-11 615,

10. Rohan, T. E., McMichael, A. J. and Bagbursi, P. A., 1988. A population-based case control study of diet and breast cancer in Australia. Am. J. Epidemic, 128, 478–489; Howe, G.R., Hiro-bata, Т., Hislap, T.G. and others. 1990. Dietary factors and risk of breast cancer, combined analysis of 12 case-control studies. J. Natl Cancer Inst., 8, 561–569; Willet, Walter C. and others, 1987. Dietary fat and the risk of breast cancer. N. Engl J. Med., 316, 22–28; Jones, D.Y., Schatzkin, A., Green, S.B. and others. 1987. Dietary fat and breast cancer in the National Health and Nutrition Examination Survey epidemiological follow-up study. J Natl Cancer Inst., 79, 465–471.

11. Trichopoulos, Dimitrios, Li, Frederick, P. and Hunter, David J., 1996. What Causes Cancer? Scientif с American, Special Issue, What you need to know about Cancer, September, 275, 3, 80–85.

12. Cramer, D.W and others, 1989. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet, 2, 66–71.

13. Stocks, P., 1970. Breast cancer anomalies. British Journal of Cancer, 24, 633–643.

14. Maruchi, N. and others, 1977. Relation of food consumption to cancer mortality in Japan, with special reference to international figures. Gann, 1977; 68, 1-13.

Глава 4

1. Сох, Peter and Brusseau, Peggy, 1995. LifePoints For Kids. Bloomsbury.

2. Statistical Abstracts of the US, 1994 edition.

3. Willett, WC. and others, 1996. Strategies for Minimizing Cancer Risk. Scientific American, Special Issue, What you need to know about Cancer, 275:3, pp, 88–95.

4. Akre, James, ed., 1989. Infant feeding: the physiological basis. WHO Bulletin, OMS Supplement, Vol. 67, and Lawrence, Ruth A., 1994. Breastfeeding: A guide for the medical profession. Fourth Edition, Mossby, USA.

5. Lawrence, Ruth A., 1994. Breastfeeding: A guide for the medical profession. Fourth Edition, Mossby, USA.

6. Lawrence, Ruth A., 1994. Breastfeeding: A guide for the medical profession. Fourth Edition, Mossby, USA.

7. Akre, James, Ed., 1989. Infant feeding: the physiological basis. WHO Bulletin, OMS Supplement, Vol. 67; and Lawrence, Ruth A., 1994. Breastfeeding: A guide for the medical profession. Fourth Edition, Mossby, USA.

8. Akre, James, Ed., 1989. Infant feeding: the physiological basis. WHO Bulletin, OMS Supplement, Vol 67, and Lawrence, Ruth A., 1994. Breastfeeding: A guide for the medical profession. Fourth Edition, Mossby, USA.

9. Akre, James Ed., 1989. Infant feeding: the physiological basis. WHO Bulletin, OMS Supplement, Vol. 67, and Lawrence, Ruth A., 1994. Breastfeeding: A guide for the medical profession. Fourth Edition, Mossby, USA.

10. American Academy of Pediatrics Committee on Nutrition (1992). The use of whole cows’ milk in infancy. Pediatrics, 89, 1105–1109.

11. Anyon, C. P. and Clarkson, K.G., 1971. A cause of iron-defi-ciency anaemia in infants. N. Z. Med. J., 74, 24–25.

12. Clyne, P.S. and Kulczycki, A. 1991. Human breast milk contains bovine IgG. Relationship to infant colic? Pediatrics, 87(4), 439–444. Wilson, J. F., Lahey, M. E. and Heiner, D.C., 1974. Studies on iron metabolism. Further observations on cow’s milk-induced gastrointestinal bleeding in infants with iron-deficiency anaemia./ Pediatr, 84, 335–344.

13. Pugh, R. H., 1981. Allergy to Cows’ Milk Protein. Health Visitor, Vol. 54, 231–233.

14. Scon, F.W, 1990. Cow milk and insulin-dependent diabetes mellitus: is there a relationship? Am J Clin Nutr, 51, 489–491.

15. Bahna, S.L., 1987. Milk allergy in infancy. Ann Allergy, 59, 131.

16. Dunea, G., 1982. Beyond the Etheric. Br. Med. /., 285, 428–429.

17. Kretchmer, N., 1981. The Significance of lactose intolerance. In: Paige, D.M. and Bayless, T.M., Eds., Lactose Digestion: Clinical and nutritional implications, Johns Hopkins University Press.

18. Chiodini, R.J. and Hermon-Taylor, J., 1993. The thermal resistance of Mycobacterium paratuberculosis in raw milk under conditions simulating pasteurisation./. Vet Diagn. Invest., 5, 629–631 and Grant, I.R., Ball, H.J., and Rowe, M.T., 1996. Inactivation of Mycobacterium paratuberculosis in cows’ milk at pasteurisation temperatures. Appl. And Env. Microbiology, 62, 631–636.

19. The Institute of Food Science & Technology Position Statement, 1998. Food Science Of Technology Today. 12 (4), 223–228, September, http://www.ifst.org/hottop23.html

20. Financial Times for the weekend 20–21 November 1999.

21. The Institute of Food Science & Technology Position Statement.

http://www.ifst.org/hottop2.html. Hard copies available from IFST, 5 Cambridge Court, 210 Shepherds Bush Road, London, W6 7NJ.

22. EU Directive 70/524 February 1999.

23. US FDA websites: http://vm.cfsan.fda.gov/—ear/ml90-1 l.ht-ml; http://vm.cfsan.fda.gov/~ear/

24. Ingersoll, Bruce, 1990. Technology and Health: FDA Detects Drugs in Milk but Fails to Confirm Results. Wall Street Journal, 6 February p86; Ingersoll, Bruce, 1990. Politics and Policy: GAO Says FDA Can’t Substantiate Claims About Milk. Wall Street Journal, 21 November pA16; and Ingersoll, Bruce, 1990.

Technology & Health: FDA Plans a Nationwide Test of Milk for Antibiotics, Other Drug Residues. Wall Street Journal, 28 December plO.

25. European Commission, Scientific Committee on Veterinary Measures relating to Public Health, 1999. Report on Public Health Aspects of the Use of Bovine Somatotropin, 15–16 March.

26. Cutwater, J.L. and others, 1997. Dairy Products and Breast Cancer: the IGF-1, estrogen and bGH hypothesis, Medical Hypotheses, 48, 453–461.

27. The Guardian, 13 July 1999.

28. McCusker, R.H., 1998. Controlling insulin-like growth factor activity and the modulation of insulin-like growth factor binding protein and receptor binding./. Dairy Sei., 81, 1790–1800.

29. The Institute of Food Science & Technology Position Statement

http:// www.easynet.co.uk/ifst/hottop8a.htm

30. Eppard, P.J. and others, 1985. Effect of dose of bovine growth hormone on milk consumption: alpha-lactalbumin, fatty acids and mineral elements./. Dairy Science Vol. 68 (11), pp. 3047–3054. See also Cohick, WS. and others, 1992. Regulation of insulin-like growth factor-binding proteins in serum and lymph of lactating cows by somatotropin. Endocrinology, 130(3), pp. 1508–1514.

31. Mepham, T.B. and others, 1994. Safety of Milk from Cows Treated with Bovine Somatotropin. Lancet, 334, November 19, 1445–1446 and Mepham, T.B. and Schonfield, P.N., 1995. Health Aspects of В ST Milk, prepared for the International Dairy Federation Nutrition Week conference in Paris, France, June 1995.

32. Simpson and others, http://www.nal.usda.gov/ttic/tekran/glimpse/data/000007/ 75/0000077539.html

33. Miller, M.A., Hildebrand, J.R., White, T.C., Hammond, E.G., Madson, K.S., and Collier, R.J., 1989. Determination of insulin-like growth factor-1 (IGF-1) concentrations in raw pasteurised and heat treated milk. Journal of Dairy Science, 72, Supplement 1, 186–187.

34. Hankinson, Susan E. and others, 1998. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 351, 9113, 9 May, 1393–1396.

35. Chan and others, 1998. Plasma IGF-1 and Prostate Cancer Risk; A Prospective Study. Science, 279, January.

36. Pollack, M.N., Huynh, H.T. and Lefebvre, S.P., 1992. Tamoxifen reduces serum insulin-like growth factor 1 (IGF-1). Br Cancer Res Treat, 22,91-100.

37. Pollack, M.N. and others, 1998. IGF-1 Risk Factor for Prostate Cancer. Science, 279, 563–566.

38. Chan and others, 1998. Plasma IGF-1 and Prostate Cancer Risk: A Prospective Study. Science, 279, January.

39. Holly, Jeff, 1998. Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet, 351, 9113, 9 May, 1373–1375.

40. Epstein, Samuel S., 1996. Unlabelled Milk from Cows Treated with Biosynthetic Growth Hormones: A Case of Regulatory Abdication. International Journal of Health Services, 26, 1, 173–185.

41. Outwater, J. L., Nicholson A. and Bernard N., 1997. Dairy products and breast cancer: the IGF-1, estrogen, and bGH hypothesis. Medical Hypotheses 48, 453–461.

42. Leonard, Rodney E., 1995. Codex at the Crossroads: Conflict on Trade Health. Nutrition Week, Vol. 25, № 26, 14 July, pp. 4–5, Nutrition Week is published by the Community Nutrition Institute, 910 17th Street, N.W, Suite 413, Washington DC 20006.

43. The European Commission. Health and Consumer Protection. Scientific Committee on Veterinary Measures relating 10 Public Health – Outcome of discussions, http://europa.eu. mt/comm/dg24/health/ sc/scv/ out 19_en.html

44. D’Ercole, J.A., Underwood, L.E. and Van Wyk, J.J., 1977. Serum Somatomedin-C in hypopituaritism and in other disorders of growth./. Pediatr, 90, 3, 375–381. See also Cullen, K.J. and others, 1990. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Research, vol. 50, pp. 48–53.

45. De Leon, D.D., Wilson, D.M., Powers, M. and Rosenfeld, R.G., 1992. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors, 6, 327–336.

46. Peyrat, J.P., Bonneterre, J. and Hecquet, B. and others, 1993. Plasma insulin-like growth factor 1 (IGF-1) concentrations in human breast cancer. Eur J Cancer, 29A, 4, 492–497.

47. Peyrat, J.P., Bonneterre, J. and Hecquet, B. and others, 1993. Plasma insulin-like growth factor 1 (IGF-1) concentrations in human breast cancer. Eur J Cancer, 29A, 4, 492–497.

48. Musgrove, E.A. and Sutherland, R.I., 1993. Acute effects of growth factors on T471 breast cancer cell cycle progression, Eur J Cancer, 29 A, 16, 2273–2279.

49. Heldrin, C.N. and Westermark, B., 1984. Growth factors: mechanism of action and relation to oncogenes. Cell, 37:9, 20.

50. Macaulay, V. М., 1992. Insulin-like growth factors and cancer. Br J Cancer, 65, 311–320.

51. Underwood, L.E., D’Ercole, J.A. and Van Wyk, J.J., 1980. So-matomedin-C and the assessment of growth. Fed ClinN Amer,

27, 4, 771–782, and Perdue, J.F., 1984. Chemistry, structure and function of insulin-like growth factors and their receptors: a review. Can J Biochem Cell Bio., 62, 1237–1245.

52. Outwater, J.L., Nicholson, A, and Barnard, N., 1997. Dairy products and breast cancer; the IGF-1 estrogen, and bGH hypothesis. Medical Hypotheses, 48, 453–461.

53. The European Commission. Health and Consumer Protection. Scientific Committee on Veterinary Measures relating 10 Public Health – Outcome of discussions. http://europa.eu.int/comm/dg24/health/ sc/scv/ outl 9_en.html

54. Council on Scientific Affairs, American Medical Association, Biotechnology and the American Agricultural Industry, 1991. Journal of the American Medical Association (JAMA), 265, 11, 20 March, p. 1433.

55. Mepham, T.B. and Schonfield, P.N., 1995. Health Aspects of BST Milk, prepared for the International Dairy Federation Nutrition Week conference in Paris, France, June 1995.

56. Challacombe. D.N. and Wheeler, E.E., 1994. Safety of milk from cows treated with bovine somatotropin. Lancet, 344, 17 September, p. 815.

57. Sell, C., Rubin, R. and Baserga, R., 1995. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-in-duced apoptosis. Cancer Research, Jan 15, 55(2), 303–306.

58. Burton, Jeanne L. and others, 1994. A review of bovine growth hormone, Canadian Journal of Animal Science, 74, 167–201.

59. Xian, C., 1995. Degradation of IGF-1 in the Adult Rat Gastrointestinal Tract is limited by a Specific Antiserum of the Dietary Protein Casein .Journal of Endocrinology, 146, 2, 1 August, p. 215, and Thornburg, W and others, 1984. Gastrointestinal absorption of epidermal growth factor in suckling rats. American Journal of Physiology, 246, G80-G85.

60. Outwater, J.L., Nicholson, A. and Barnard, N., 1997. Dairy products and breast cancer; the IGF-1 estrogen, and bGH hypothesis. Medical Hypotheses, 48, 453–461.

61. Harasuchi, S., Good, R.A., Engelman, R.W and Day, N.K., 1992. Human prolactin regulates transfected MMTV LTR-di-rected gene expression in a human breast-carcinoma cell line through synergistic interaction with steroid hormones. Int J Cancer, 52, 923–933.

62. Clevenger, C,V, Chang, WF., Ngo, W, Pasha, T.L., Montone, K.T. And Tomaszewski, J. E., 1995. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop .Am J Pathol, 146, 695–705.

63. Vonderhaar B.K., 1989. Estrogens are not required for prolactin induced growth of MCF-7 human breast cancer cells. Cancer Lett, A7, 105–110.

64. http://www.shef.ac.uk/uni/academic/a-c/csi/1997/pir2.html

65. Lochnan, H.A. and others, 1995. Functional activity of the human prolactin receptor and its ligands. Mol. Cell. Endocrinol, 114, 91–99.

66. http://mammary.nih.20v/reviews/tumorigenesis/Vonderhaar 001/ slides/introduction.html

67. Struman, I., Bentzien, F., Lee, H., Mainfroid, V, D’Angelo, G., Goffin, V., Weiner, R.I. and Martial, J.A., 1999. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sei USA, 96, 1246–1251.

68. http://www.eurekalert.org/releases/upmc-bcc061699.html

69. Lawrence R., 1994. Breastfeeding – A Guide to the Medical Profession, Fourth edition, Mossby, USA.

70. http://www.inter-medico.com/prolactin.html

71. Lawrence, R., 1994. Breastfeeding: A Guide for the Medical Profession. Fourth edition, Mossby, USA.

72. Poggi, S.H., Skinner, H., Catherine W and others, 1998. Using scanning electron microscopy to study mineral deposits in breast tissues. American Mineralogist, 83, 1122–1126.

73. Lee, J.R., 1996. Natural Progesterone. John Carpenter Publishing, Oxfordshire, 113 pp.

74. Wolford, S.T. and Argoudelis, C.J., 1979. Measurement of Estrogens in Cow’s Milk, Human Milk and Dairy Products. /. Dairy Sei., 62(9), 1458–1463.

75. Outwater, J.L., Nicholson, A. and Barnard, N., 1997. Dairy products and breast cancer; the IGF-1 estrogen, and bGH hypothesis. Medical Hypotheses, 48, 453–461.

76. The European Commission. Health and Consumer Protection. Scientific Committee on Veterinary Measures relating to Public Health – Outcome of discussions. 1999, Report on Public Health Aspects of the Use of Bovine Somarotropin. http://europa.eu.int/com m/d g2 4/health/s c/s cv/outl9_ en.html

77. Allen, N.E., and others, 2000. Hormones and Diet: Low Insulin-like Growth Factor-1 but Normal Bioavailable Androgens in Vegan Men. Brit. J. Cane., 83 (1), 95–97.

78. Chan, J.C., and others, 1998. Plasma TGF-1 and Prostate Cancer Risk: A Prospective Study. Science 279, January.

79. Kradjian, R.D., 1994. Save Yourself from Breast Cancer, Berkley Books, New York.

Глава 5

1. Wright, K., 1996. A plea for prevention. Scientific American, September. (Inset p.99 in article by Greenwald 1996, see below ref. 20).

2. Collaborative Group on Hormonal Factors in Breast Cancer, 1996. Lancet, 347, 1713–1727.

3. http://www.who.int/nut/malnutrition_worldwide.html

4. The Times, 2 November 1999.

5. Riggs, B.L., Wahner, H.W, Melton, L.J. 3rd, Richelson, L.S., Judd, H.L. And O’Fallon, WM., 1987. Dietary calcium intake and rates of bone loss in women. / Clin Invest, Oct, 80, 4, pp. 979–982.

6. Hegsted, D.M., 1986. Calcium and Osteoporosis./Nutr, 116, 2316–2319.

7. Kim, J.B., 1990. Fractured truths. Bestways vl8, n2, p26(7).

8. Kim, J.B., 1990. Fractured truths. Bestways vl8, n2, p26(7).

9. http://www.who.int/nut/malnutrition_worldwide.html

10. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Department of Health, 1991.

11. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Department of Health, 1991. P. 139, table 22.2.

12. Havaia, S. and Dwyer, J., 1988. Position of the American Dietetic Association: Vegetarian Diets – technical support pa-per .J Am Diet Assoc, 88:3 352–355.

13. Barnard, N., 1993. Food for life, Harmony Books.

14. ‘Research Advances in Osteoporosis’, 1990. Conference by the National Osteoporosis Foundation, the National Institutes of Health, and the American Society of Bone and Mineral Research, Arlington, Virginia, USA February.

15. Heaney, R.P. and Weaver, C.M., 1990. Calcium absorbability from kale.^LwJ Clin Nutr, 51, 656–657.

16. Breslau, N.A., Brinkley, L., Hill, K.D. and Pak, C.Y., 1988. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism./ Clin EndocrinolMetah, Jan, 66,

1, pp. 140–146.

17. Heaney, R.P. and Recker, R.R., 1982. Effects of nitrogen, phosphorus, and caffeine on calcium balance in women. J Lab Clin Mod, Jan, 99, 1, pp. 46–55.

18. Pritchard, K.I. and others, 1996. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer, Journal of Clinical Oncology, vol. 14 (10), 2731–2738.

19. Gooderham, M.J., Adlercreutz, H., Sirpa, T.O., Wahala, K. and Holub, B.J., 1996. A Soy Protein Isolate Rich in Genistein and Daidzein and its Effects on Plasma Isoflavone Concentrations, Platelet Aggregation, Blood Lipids and Fatty Acid Composition of Plasma Phospholipid in Normal Men. J. Nutr., 126, 2000–2006.

20. Greenwald, Peter, 1996. Chemoprevention of Cancer. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 96–99.

21. Kurzer, M.S. and Xu, X., 1999. Dietary Phytoestrogens. Annual Reviews of Nutrition, Vol. 17, pp. 353–381.

22. Shurtleff, William and Aoyagi, Akiko, 1975. The Book: of Tofu. Autumn Press Inc.

23. Kurzer, M.S. and Xu, X., 1999, Dietary Phytoestrogens. Annual Reviews of Nutrition Vol. 17, pp. 353–381.

24. UK Ministry of Agriculture, Fisheries and Food advice as reported in the Sunday Times, 1999.

25. Willet WC., 1994. Micronutrients and cancer risk. Am J Clin Nutr, 59, (suppl), 1162S-5S. See also: Willett, Walter C., Colditz, Graham A. and Mueller, Nancy A., 1996, Strategies for Minimising Cancer Risk. Scientific American, Special Issue, «What you need to know about Cancer, September», 275, 3, 88–95.

26. Greenwald, Peter, 1996. Chemoprevention of Cancer. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 96–99.

27. Levy, J., Bosin, E., Feldman, B., Giat, Y., Milnster, Danilenko, M. and Sharoni, Y, 1995. Lycopene is more potent inhibitor of human cancer cell proliferation than either A-carotene or B-carotene. Nutr Cancer, 24, 257–266.

28. Nagasawa, H., Mitamura, Т., Sakamoto, S, and Yamamoto, K., 1995. Effects of lycopene on spontaneous mammary tumour development in SHN virgin mice. Anticancer Res. 15, 1173–1178.

29. Willett, Walter C., Colditz, Graham A. and Mueller, Nancy A., 1996. Strategies for Minimising Cancer Risk. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 88–95.

30. Ortega, R.M. and others, 1996. Functional and Psychic Deterioration in Elderly People may be aggravated by folate deficiency. / Nutr., 126, 1992–1999.

31. Phipps, WR., Martini, M.C., Lampe, J.W, Slavin, J.L. and Kurzer, M.S., 1993. Effect of flax seed ingestion on the menstrual cycle./ Clin EndocrinolMetab., 77, 5, November, 1215–1219.

32. www.flax.com.fda

33. Greenwald, Peter, 1996. Chemoprevention of Cancer. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 96–99.

34. Coghlan, Andy, 1999. Crunch Time for Cancer. New Scientist, 13 November, 264, 2212.

35. Pinto, J.T., Qiao, C.H., Xing, J., Rivlin, R.S., Protomastro, M.L., Weissler, M.L. and Hesion, WD.W, 1999. Effects of garlic thioallylic derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am. J. Clin. Nutr. See also: Li, G., Qiao, C.H., Lin, R.I., Pinto, J., Osborne, M.F., and Tiwari, R.K., 1995, Antiproliferative effects of garlic constituents in cultured human breast cancer cells. Oncology Rpts., 2, 787–791.

36. www.3mistral.co.uk/garlic/cancer.htm;www.mskcc.org/rande/ pharmacology/189.html

37. Greenwald, Peter, 1996. Chemoprevention of Cancer. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 96–99.

38. Doll, R. and Peto, R., 1981. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. New York: Oxford University Press.

39. Lang, T. and Clutterbuck, C., 1991. P is for Pesticides, Ebury Press, Random Century Group, 256p.

40. McMichael, A.J., 1993. Planetary Overload – Global Environmental Change and the Health of the Species. Cambridge University Press.

41. Lang, T. and Clutterbuck, C., 1991. P is for Pesticides, Ebury Press, Random Century Group, 256p.

42. http://www.radian.com/standards; http://ro-systemsnet/atra-zine.html

43. Stevens and others, 1994. http://www-oem.ucdavis.edu~beaumont/Agrichem/herbi-cides/triazine/triazine.html

Stevens, J.T. and Sumner, D.D., 1991. Herbicides, in Handbook of Pesticide Toxicology 3 Vol. 3. Classes of Pesticides , Toronto: Academic Press Inc, 1317–1408. See also Environmental Endocrine Disrupters: A handbook of property data, 1999.

44. http://who-pcc.iarc.fr/

45. Hambridge, K. M., Casey, C. E. and Krebs, N. E, 1986, Zinc, In: Trace Elements in Human and Animal Nutrition, Fifth Edition, Mertz, W, Ed. Academic Press, Inc, London.

46. McCusker, R.H., 1998. Controlling Insulin-Like Growth Factor Activity and the Modulation of Insulin-Like Growth Factor Binding Protein and Receptor Binding. J Dairy Sei, 81, 1790–1800.

47. Simpson and others. Effect of exogenous estradiol on plasma concentrations of somatotropin, insulin-like growth factor 1, insulin-tike growth factor-binding protein activity and metabolites in ovariectomised Angus and Brahman cows. http://www.nal.usda.gov/ttic/tektran/glimpse/data/000007/ 75/0000077539.html

48. The Globe and Mail 3l July 1999.

49. Hendler, S.S., 1990. The Doctors' Vitamin and Mineral Encyclopaedia,, Simon and Schuster, New York.

50. Hetzel, B.S., and Maberly, G. E., 1986. Iodine, In: Trace Elements in Human and Animal Nutrition, Fifth Edition, Mertz, W, Ed. Academic Press, Inc, London.

51. Eskin, B.A., Shuman, R., Krouse, Т., Merion, J.A., 1976. Rat mammary gland atypia produced by iodine blockade with perchlorate. Cancer Res, 35(9), 2332–2339. See also Eskin, B.A., 1978. In: Inorganic and Nutritional Aspects of Cancer. Schrau-zer, G.N., ed., 293–304, Plenum Press, New York. This reference is quoted in Grouse, Robert G., Pories, Walter J., Bray, John T. and Mauger, Richard L., 1983. Geochemistry and Man: Health and Disease 1. Essential Elements. In: Applied Environmental Geochemistry. Thornton, I., Ed. London, Academic Press, 267–308.

52. Johnson, C., 1999, Environmental controls in iodine deficiency disorders (TDD), Earthworks, 9 November, p. 3, British Geological Survey.

53. Simopoulos, A.P., 1991. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr., 54, 438–463.

54. Simopoulos, A.P., 1991. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr., 54, 438–463. See also Fernandes, G. and Venkatraman, J.T., 1993. Role of omega-3 fatty acids in health and disease. Nutr. Res., 13, S19-S45.

55. Reported in the London Evening Standard, 17 March 1989. See also Wilier W C., 1994, Micronutrients and cancer risk. Am J Clin Nutr, 59, (suppl), 1162S-1165S.

56. Hunter, David J. and Willett, Walter C., 1993. Diet and Body Build: Diet, Body Size and Breast Cancer, Epidemiologic Reviews, 15, 1, 110–132.

57. Ingram, A. J. and others, 1995. Effects of a Flaxseed and Flax Oil Diet in a Rat – 5/6 Renal Ablation Model. American Journal of Kidney Disease, February 25, 2, 320–329.

58. Obermeyer, WR., Musser, S.M., Betz, J.M., Casey, R.E., Pohland, A.E. and Page, S.W, 1995. Chemical studies of phytoestrogens and related compounds in dietary supplements – flax and chaparral. Proceedings of the Society for Experimental Biology and Medicine. See also Obermeyer, WR., Warner, C., Casey, R.E. and Musser, S., 1993, Flaxseed lignans isolation metabolism and biological effects. Fed Am Soc Exp Biol, J., A863.

59. Dupont, J., White, P.J., Johnston, K.M. and others, 1989. Food safety and health effects of canola oil .J Am Coll Nutr., 8, 360–375.

60. Kohlmeier, L, and others, 1997. Adipose tissue trans fatty acids and breast cancer in the European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer, Cancer Epidemiol. Biomarkers prev., 6, 9, 705–710.

61. Koletzko, B., 1992. Trans fatty acids may impair biosynthesis of long-chain polyunsaturates and growth in man. Acta Paedia-tr., 81, 302–306.

62. Trichopoulos, Dimitrios, Li, Frederick, P. and Hunter, David J, 1996. What Causes Cancer? Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 80–85.

63. Forbes, Alec, 1984. The Bristol Diet, Century.

64. Ingram, A.J., Parbtani, A., Clark, WF, Spanner, E., Huff, M.W, Philbrick, D.J. and Holub, B.J., 1995. Effects of flaxseed and flax oil diets in a rat-5/6 renal ablation model. Am J Kidney Dis., February, 25, 2, 320–329.

65. Lee, S. and others, 1999. Monitoring of Drinking Water in terms of Natural Organic Matter and Disinfection By-products. Proc 2nd Intern. Symp. On Advanced Env. Monitoring, Kwangju, Korea.

66. Herrick, D., 1996. Cryptosporidium and Giardia: Should you be concerned? Water Well Journal, 50, 4, 49, 44–46.

67. Jankun, Jerzy, Seiman, Steven H., Swiercz; Rafal and Skrzypc-zak-Jankun, Ewa, 1997. Why drinking green tea could prevent cancer. Nature, 387, 15 June, p. 561 see also: Greenwald, Peter, 1996. Chemoprevention of Cancer, Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 96–99.

68. Jankun, Jerzy, Seiman, Steven H., Swiercz, Rafal and Skrzypc-zak-Jankun, Ewa, 1997. Why drinking green tea could prevent cancer. Nature, 387, 15 June, p. 561.

69. Campion, K., 1986. Vegetarian Encyclopaedia, Century Hutchinson Ltd, London.

70. Jankun, Jerzy, Seiman, Steven H., Swiercz, Rafal and Skrzypc-zak-Jankun, Ewa, 1997. Why drinking green tea could prevent cancer. Nature, 387, 15 June, p. 561.

71. http://research.kib.ki.se/e-uven/public/51419.html

72. Lockwood, K., Moesgaard, S., Hanioka, T. and Fotkers, K., 1994. Apparent partial remission of breast cancer in chigh risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol aspects Mod, 15, Suppis, 231–240.

Lockwood, K., Moesgaard, S, and Folkers, K., 1994. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochemical and Biophysical Research Communications, 199, 3, March 30, 1504–1508. Lockwood, K., Moesgaard, S., Yamamoto, T. and Folkers, K., 1995. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochemical and Biophysical Research Communications, 212. 1, 172–177.

Глава 6

1. Gerhard Schrauzer, Ph.D., of the University of California cited in Better Nutrition, Nov, 1989, v 51, no. 11, p. 14 (2).

2. Redhook., April, 1989, v 172, n6, p. 96 (5).

3. Spallholz, J.E., Stewart, J.R., 1989. Advances in the role of minerals in immunobiology. Center for Food and Nutrition, Texas Tech University, Lubbock 79409. Biol Trace Elem Res Mar, 19 (3) pp. 129–151.

4. Archives of Environmental Health, September/October 1976.

5. Knekt, Paul, and others, 1988. Selenium Deficiency and Increased Risk of Lung Cancer. Abstract of paper read at the Fourth International Symposium on Selenium in Biology and Medicine, Tubingen, West Germany, July.

6. Reinhold, U., and others, 1988. Selenium Deficiency and Lethal Skin cancer. Abstract of paper read at the Fourth International Symposium on Selenium in Biology and Medicine, Tubingen, West Germany, July.

7. Lockwood, K., Moesgaard, S., Hanioka, Т., and Folkers, K., 1994. Apparent partial remission of breast cancer in chigh risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Qi0. Mol Aspects Med, 15, Suppls, 231–240. See also: Lockwood, K., Moesgaard, S. and Folkers, K., 1994. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochemical and Biophysical Research Communications, 199, 3, 30 March, 1504–1508. See also: Lockwood, K., Moesgaard, S„Yamamoto, T. and Folkers, K., 1995. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochemical and Biophysical Research Communications, 212, 1, 172–177.

8. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man, 1982. Geneva: World Health Organization, International Agency for Research on Cancer, 1972 – present. (Multivolume work). V29, p. 282. See also Osihi, Shinshi, 1990. Effects of phthalic acid esters on testicular mitochondrial functions in the rat Archives of Toxicology, March, V64 n2, p. 143 (5).

9. Holland, J C., 1996. Cancer’s Psychological Challenges. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 158–161.

10. Heason, P., Deep Relaxation available from 37 Tollerton Lane, Tollerton, Nottingham.

11. Based on Holland, J C., 1996. Cancer’s Psychological Challenges. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 158–161.

12. Trichopoulos, Dimitrios, Li, Frederick, P. and Hunter, David J., 1996. What Causes Cancer? Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 80–85.

13. Levy, Len, 1998, Biomed II: Exposure to low-level benzene, p. 76. In: Institute for Environment and Health, Annual Report. 100 pp.

14. Pearson, J.K., 2000. The Air Quality Challenge, American Society of Automotive Engineers and HMSO.

15. North Atlantic Treaty Organisation, 1988. International Toxicity Equivalency Factor (I-TEF) method of risk assessment for complex mixtures of dioxins and related compounds. Pilot study on international information exchange on dioxins and related compounds. CCMS Report Number 176, Environmental Protection Agency, Washington DC, USA. Department of Health, 1995. Statement by the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment on the US EPA draft, health assessment document for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Dept of Health, London.

16. EPA Dioxin Reassessment Summary, 1994 4/94 – Vol. 1, CERI/ORD Publication Centre, USEPA.

17. MAFF, 1997. Dioxins and PCBs in retail cows’ milk in England. Food Surveillance No. 136, December, Ministry of Agriculture, Fisheries and Food, London.

18. Tanabe, S., 1988. PCB Problems in the Future: Foresight from Current Knowledge. Environmental Pollution, 50, 5-28.

19. Department of the Environment, 1989. Dioxins in the Environment Pollution Paper, No. 27, HMSO, London.

20. MAFF, 1997. Dioxins and Polychlorinated Biphenyls in Fish Oil Dietary Supplements and Licensed Medicines. Food Surveillance Information Sheet, № 106, Ministry of Agriculture, Fisheries and Food, London.

21. MAFF, 1996. Dioxins In Human Milk. Food Surveillance Information Sheet, № 88, Ministry of Agriculture, Fisheries and Food, London.

22. MAFF, 1996. Polychlorinated Biphenyls in Food – UK Dietary Intakes. Food Surveillance Information Sheet, № 89, Ministry of Agriculture, Fisheries and Food, London.

23. Environmental Endocrine Disruptors: A Handbook of Property Data, John Wiley and Sons.

24. Shin, R.J. and others, 1999. Development of a bioassay system for identification of Endocrine Disrupters. Proc 2nd Intern. Symp. On Advanced Env. Monitoring, Kwangju, Korea.

25. Soto, A.M. and others, 1992. An in culture bioassay to assess the estrogenicity of xenobiotics. In: Chemically-induced alterations in sexual and functional development. The wildlife/ human connection. Vol. 21, Colborn T.C, Clement ed., Princeton Scientific Publishing, 295–309. See also: Soto, A.M. and others, 1995. The E-SCREEN assay as a tool to Identify estrogens: An update on estrogenic environmental pollutants. In: Estrogens in the Environment, Environmental Health Perspectives,113–122.

26. Davis, Devra Lee, Axelrod, Deborah, Osborne, Michael P. and Telang, Nitin Т., 1997. Environmental influences on Breast Cancer Risk, World Resources Institute, Washington, DC, USA, Science and Medicine. May/June.

27. Colborn, Т., Dumanoski, D. and Myers, J.P., 1996. Our Stolen Futures, Dutton, Penguin Books, USA.

28. Dyson, Т., 1999. Prospects for feeding the world. British Medical Journal, 319, 988–991.

29. Reuters, 8 October 1998.

30. McMurry, Laura М., Oethinger, Margaret, Levy, Stuart B., 1998. Triclosan targets lipid synthesis. Nature, 394, 6693, 531–532.

31. Trichopoulos, Dimitrios, Li, Frederick, V. and Hunter, David J, 1996. What Causes Cancer? Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 80–85.

Глава 7

1. Campbell, T.C. and Junshi, C., 1994. Diet and chronic degenerative disease perspectives from China. Am. J Clin. Nutr, 59, Suppl., 11 535-11 615.

2. Packham, D.E., 1999. Impacts of Commercialisation and Privatisation on Capabilities for Scientific Advice, Oracles or Scapegoats? IPMS Conference notes. October.

3. Packham, D.E., 1999. Impacts of Commercialisation and Privatisation on Capabilities for Scientific Advice, Oracles or Scapegoats? IPMS Conference notes, October.

4. Association of University Teachers. Efficiency Gains or Quality Losses? 1996 (Based on DfEE and Welsh Office figures).

5. Bok, D., 1990. In: Universities and the Future of America, Duke University Press, Durham NC.

6. Glantz, S.A., 1996. Times Higher Education Supplement, 6 September, p. 15. and Glantz, S.A.,Slade, J., Bero, L.A., Hanauer, P. and Barnes, D.E., 1996. The Cigarette Papers, University of California Press.

7. Packham, D.E., 1999. Impacts of Commercialisation and Privatisation on Capabilities for Scientific Advice, Oracles or Scapegoats? IPMS Conference notes, October. See also: Packham, David and Tasker, Mary, 1997. Industry and the academy – a Faustian contract. Industry and Higher Education, April, 85–90.

8. Packham, D.E., 1999. Impacts of Commercialisation and Privatisation on Capabilities for Scientific Advice, Oracles or Scapegoats? IPMS Conference notes, October. See also: Packham,

David and Tasker, Mary, 1997. Industry and the academy– a Faustian contract. Industry and Higher Education, April, 85–90.

9. Jasanoff, S., 1997. Civilization and madness: the great BSE scare of 1996. Public Understand. Sei. 6, 221–232.

10. McMichael, A.J. and Powles, J.W, 1999. Human numbers, environment, sustainability and health. British Medical Journal, 319, 9 October, 977–980.

Дополнение к главе 1

1. www.nlm.nih.gov/medlineplus/ency/article/002919.htm

2. McKenna, Claire, 2002. UK has highest reduction in deaths from lung and breast cancer. BMJ, 325, 63.

3. Irwig, Les, 2006. Evaluating new screening tests for breast cancer. BMJ, 332, 678–679.

4. Anon, 2006. Screening for breast cancer. BMJ, 332, 499–500.

5. www.nlm.nih.gov/medineplus/ency/article/002919.htm

6. e.g. Baum, М., 2000. Survival and reduction in mortality from breast cancer – Impact of mammographic screening is hot clear (Letter). BMJ, 321, 1470.

7. Spurgeon, David, 2002. Annual mammography in women in their 40s does not cut death rate. BMJ, 325, 563.

8. Spurgeon, David, 2002. Annual mammography in women in their 40s does not cut death rate. BMJ, 325, 563.

9. Josefson, Deborah, 2002. Breast self-examination does not improve cancer survival. BMJ, 325, 793.

10. Zackrisson S. and others, 2006. Rare of over-diagnosis of breast cancer 15years after end of Malmo mammographic screening trial; follow up study. BMJ, 332, 689–692.

11. Anon, 2006. Screening for breast cancer. BMJ, 332, 499–500.

12. Symonds, R. Paul, 2002. Cancer biology may be more important than diagnostic delay. BMJ, 325, 774.

13. Spurgeon, David, 2002. Annual mammography in women in their 40s does not cut death rate. BMJ, 325, 563.

14. www.cancerscreening.nhs.uk/breastscreen

15. White, Caroline, 2002. ‘Unacceptable’ errors found in breast screening process. BMJ, 324, 933.

16. UK National Radiological Protection Board, www.nrpb.org/ radiation_topics/risks/exposure.htm

17. Irwig, Les, 2006. Evaluating new screening tests for breast cancer. BMJ, 332, 678–679.

18. www.well-connected.com/rreports/doc06full.html

19. www.well-connected.con’i/rreports/doc06full.html

20. Keyomarsi, K., Tucker, S.L., Buchholz, T.A., Callister, M., Ding, Y., Hortobagyi, G.N., Bedrosian, I. Knickerbocker, C., Toyofuku, W, Lowe, M., Herliczek, T.W, and Bacus, S.S., 2002. Cyclin E and Survival in Patients with Breast Cancer. N Engl J Med, 347, 1566–1575.

21. Yancik, R. and Ries, L.A., 1994. Cancer in older persons. Magnitude of the problem – how do we apply what we know? Cancer, 74 (7 Suppl), 1995–2003.

22. Silliman, R.A. and Baeke, P., 1998. Breast cancer in the older woman. In: Balducci, L., Ersher, W B. and Lyman, G.H., Comprehensive geriatric oncology. Amsterdam: Harwood.

23. Welch, H.G., Albertson, EC., Nease, R.E, Bubolz, T.A. and Wasson, J.H., 1996. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med, 124, 577–584.

24. Holmes, EE, 1994. Clinical course of cancer in the elderly. Cancer Control, 1, 108–114.

25. Nixon, A.J., Neuberg, D., Hayes, D.E, Gelman, R., Connolly, J.L., Schnitt, S. and others, 1994. Relationship of patient age to pathological features of the tumor and prognosis for patients with stage I or II breast cancer./ Clin Oncol, 12, 888–894.

26. Balducci, Lodovico and Phillips, D. Melissa. 1998. Breast cancer in older women. American Family Physician. October 1, 1998. www.aafp.org/afp/981001 ap/balducci.html

27. www.well-connected.com/rreports/doc06full.html

28. Medical Report: Prostate Cancer. ICON, 2002, 1 (5), 8-10.

29. Waxman, Jonathan, 2001. The Prostate Cancer Book. London: Vermillion.

30. http://www.nccn.org/paticnt_gls/_english/_prostate/

31. http://www.nccn.org/patient_gls/_english/_prostate/

32. Hart, D. and Wall, 2004. UK population dose from medical examinations. European Journal of Radiology, 50 (3), 285–291, Brenner, D.I. and others, 2001. CT scanning of children has been calculated 10 increase their lifetime risk of cancer. American Journal of Roentology, 176, 289–296.

33. http://www.nccn.org/patient_gls/_english/_prostate/

34. http://www.cancer.org

35. Spurgeon, David, 2003. Advanced scanning techniques help doctors stage prostate cancer. BMJ, 326, 1418.

36. New England Journal of Medicine, 2003, 348, 2491–2499.

37. http://www.nccn.org/patient_gls/_english/_prostate/

38. Fisher, B. and others, 2002. Twenty year follow-up of a randomised trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine, 347 (16), 1233–1241.

39. Fisher, B., Bryant, J., Dignam, J.J., Wickerham, D.L., Mamou-nas, E.F., Fisher, E.R., Margolese, KG., Nesbitt, L., Paik, S., Pisansky, T.M., Wolmark, N., 2002. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less./ Clin Oncol, 20 (20), 4141–4149; www.ncbi.nlm.nih.gov; 80

40. Fisher, B., Anderson, S., Bryant, J., Margolese, R.G., Deutsch, M., Fisher, E.R., Jeong, J.H. and Wolmark, N., 2002. Twenty-year follow-up of a randomised trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 347 (16), 1233–1241; www.ncbi.nlm.nih.gov; 80

41. Gottlieb, Scott. Lumpectomy is as effective as mastectomy for breast cancer. BMJ, 325, 921.

42. www.nlm.nih.gov/medlineplus/ency/article/002919.htm

43. www.nlm.nih.gov/medlineplus/ency/article/002919. htm

44. www.cancer.org/docroot/cri/content/cri_2_6x_breast_recon-struction_after_mastectomy_5.asp

45. Bartelinkh and others, 2001. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. New England J Med, 345 (19), 1378–1387.

46. http://cis.nci.nih.gov/fact/7_l6.htm

47. Morrow, Monica and Gradishar, William, 2002. Recent Development: Breast Cancer. BMJ, 324, 410–414.

48. Coombes, R.C. and others, 2006. American Society of Clinical Oncology, Annual Meeting, Atlanta Georgia, June 2006.

49. Gralow, Julie R., 2002. Bisphosphonates as adjuvant treatment for breast cancer. BMJ, 325, 1051–1052.

50. www.gene.com/gene/products/information/oncology/ herceptin;

www.herceptin.com/herceptin/ physician/pi.htm

51. www.herceptin.com/herceptin/physician/pi.htm

52. Anon, 2006. Patient is to appeal High Court ruling on breast cancer drug. BMJ, 332–443.

53. Barrett, A. and others, 2006. How much will herceptin really cost? BMJ, 333, 1118–1120.

54. Daily Mail, Monday, 9 October, 2006.

55. www.ahrq.gOv/news/press/pr2002/brchempr.htm

56. http://cis.nci.nih.gov/fact/7_ 16.htm

56. http://cis.nci.nih.gov/fact/ 7_16. htm

57. Gottlieb, Scott, 2002. Tamoxifen may increase risk of uterine sarcoma, BMJ, 325, 7.

58. http://cis.nci.nih.gov/fact/7_16. htm

59. Mayor, Susan, 2002. Anastrozole shows promise for early breast cancer. BMJ, 324, 1539

60. www.gene.com/gene/products/information/oncology/hercep-tin;

www.herceptin.com/herceptin/physician/pi.htm

61. http://cis.nci.nih.gov/fact/7_45. htm

62. www.ahrq.gov/news/press/pr2002/brchempr.htm

63. New Scientist, 20 January, 2007.

64. Editorial, New Scientist, 31 March, 2007.

65. Josefson, Deborah, 2002. Doctors warned to be wary of new drugs. BMJ, 324, 1113.

66. Garattini, Silvio and Bertele, Vittorio, 2002. Efficacy, safety, and cost of new anticancer drugs. BMJ, 325, 269–271.

67. www.cancer.gov

68. Modified after: Chemotherapy and You: A Guide to Self-Help During Cancer Treatment. Information about what to expect during chemotherapy and what patients can do to take care of themselves during and after treatment NIH Publication #99-1136: www.cancer.gov/cancerinfo/chemorherapy-and-you

69. Smith, I. and Chue, S., 2006. Medical treatment of early breast cancer. BMJ, 332, 162–181.

70. Allison, R. and others, 2006.Photodiagnosis and photodynamic therapy, 3, 139–146.

71. Fritsch, С. and Ruzika, Т., 2003. Fluorescence diagnosis and photodynamic therapy of skin diseases atlas and handbook. Vien: Springer-Verlag.

72. Coulter; Angela, 2003. Killing the goose that laid the golden egg. BMJ, 326, 1280.

73. Coulter, Angela, 2003. Killing the goose that laid the golden egg. BMJ, 326, 1280.

74. Ernst, E., 2003. Herbal medicines put into context. BMJ, 327, 881–882.

75. Waxman, Jonathan, 2001. The Prostate Cancer Book. London: Vermillion.

76. Dyer, Owen, 2003. Aspirin could be used to prevent cancer. BMJ, 326, 565.

77. Flower, Rod, 2003. What are all the things that aspirin does? BMJ, 327, 572–573.

78. UK limits use of aspirin by under 16s. BMJ, 2002, 324, 1294.

79. Astralagus. ICON, 2002, 1 (3), 23.

80. Bartram, Т., 1998. Bartram’s encyclopedia of herbal medicine. Robinson publishing.

81. Campbell, T.C. and Campbell, T.M., 2006. The China Study. Benbella Books.

82. Greenwald, Peter, 2002. Cancer chemoprevention. BMJ, 324, 714–718.

Дополнение к главе 2

1. Clarke, M.F. and Becker, M.W, 2006. Stem cells: the real culprits in cancer? Scientific American, July 2006, 53–59.

2. Study reveals how growth factors affect human stem cells. www.hhmi.org/news/melton.hmtl

3. Murray, R.K., Granner, D.K., Mayes, P.A. and Rodwell, VW, 1990. Harper's Biochemistry. Appleton and Lange Norwalk, CT, p. 653.

4. Woolf, Neville, 1998. Pathology, Basic and Systemic. WB. Saunders Publishing Co., Chapter 28, p. 274, Figure 28.

5. www.intouchlive.com/cancergenetics/onco.htm

6. Ludwig, Т., Fisher, P., Ganesan, S. and Efstratiadis, 2001. Tum-origenesis in mice carrying a truncating BRCA1 mutation. Genes and Development, Vol. 15 (10), 1188–1193.

7. Xu, X., Wagner, K.U., Larson, D., Weaver, Z., Li, C., Ried, Т., Hennighausen, L., Wynshaw-Boris, A. and Deng, C.X. 1999. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, Vol. 22 (1), 37–43.

8. Pauli, T.T, Cortez, D., Bowers, B., Elledge, S.J. and Geliert, M., 2001. Direct DNA binding by BRCA1. Proceedings of the National Academy of Sciences of the USA, Vol. 98 (11), 6086–6091.

9. Jensen, R.A., Thompson, M.E., Jetton, T.L., Szabo, C.I., van der Meer, R., Helou, В., Tronick, S., King, M.C., Page, D.L. and Holt, J.T., 1996. BRCA1 is secreted and exhibits properties of a granin. Nature Genetics, 12, 303–308; www.mc.vander-bilt.edu/cancer/research/ roster/jensen.html

10. Struewing, J.P., Abeliovich, D., Peretz, Т., Avishai, N., Kaback, M.M., Collins, F.S. and Brody, L.C., 1995. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi-Jewish individuals. Nature Genetics, 11, 198–200;

http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html

11. Roa, B.B., Boyd, A.A., Volcik, K. and Richards, C.S., 1996. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14, 185–187; Oddoux, C., Struewing, J.P., Clayton, C.M., Neuhausen, S., Vrody, L.C., Kaback, M., Haas, B., Norton, L., Borgen, P., Jhanwar, S., Golgar, D., Ostrer, H. and Offit, K., 1996. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %. Nature Genetics, 14, 188–190; http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html

12. www.mercola.com/2002/apr/27/sv40.htm

13. Hursting, S.D., Slaga,T.J., Fischer, S.M., DiGiovanni, J. and Phtans, J. M., 1999. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. Journal of the National Cancer Institute, 35, 2031–2038.

14. Cheeseman, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.

15. Cheesernan, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.

16. Stewart, H.J., 1989. Clinical experience in the use of antioestrogen tamoxifen in the treatment of breast cancer. Proceedings of the Royal Society of Edinburgh, 95B, 231–237.

17. Miller, W R., 1997. Aromatase inhibitors and breast cancer. Cancer Treatment Reviews, 23, 113–131.

18. Dao, T.L., Sinha, D.K., Nemato, T. and Patel, J., 1982. Effects of estrogens and progesterone on cellular replication of human breast tumours. Cancer Research, 42, 359–362.

19. Conte, P.P., Fraschini, G. and Dewinko, B., 1985. Estrogen induced expansion of the growth fraction in receptor negative human breast cancer.Journal of Steroid Biochemistry, 23, 1169–1172.

20. Miller, WR. and Langdon, S.P., 1997. Hormonal, growth factor and cytokine control of breast cancer. In: Biology of Female Cancers, pp. 43–60. Langdon, S,P., Miller, WR. and Berchuck, A. (editors). New York: CRC Press.

21. Miller, WR., 1991. Oestrogens and breast cancer: biological considerations, British Medical Bulletin, 47, 470–483.

22. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

23. Rose, Steven, with Mileusnic, Radmila, 1999. The Chemistry of Life. Fourth (revised) edition. Penguin Books.

24. Voet, Donald and Voet, Judith, 1995. Biochemistry. Second edition. John Wiley & Sons, Inc.

25. Jiang, Wen G., Matsumoto, Kunio and Nakamura, Toshikazu (editors), 2001, Growth Factors and their Receptors in Cancer Metastasis. Dordrecht: Kluwer Academic Publishers.

26. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

27. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

28. www.ucop.edu/srphome/bcrp/progressreport/abstracts/ innov/3CB-0186.html

29. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

30. www.preventcancer.com/pdf/InsulinGrowth266.html

Дополнение к главе 3

1. www.dep.iarc.fr/globocan/database.pdf

2. WHO International Agency for Research on Cancer (IARC), IARC Cancer Epidemiology Database. GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide. Ferlay, J., Bray, F., Piesci, P. and Parkin, D.M. (editors), www.dep.iarc. fr/globocan/ database.pdf

3. American Cancer Society. Modelled data: cancer facts and figures, 2006.

4. www.cancerresearchuk.org

5. www.cancerresearchuk.org

6. www.cancerresearchuk.org

7. Pike M.C., Kolonel, L.N., Henderson, B.E., Wilkens, L.R., Hankin J.H., Feigelson, H.S., Wan, P.C., Stram, D.O. and Nomura, A.M., 2002. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev, 11 (9), 795–800.

8. www.hawaii.edu/crch/ProfileKolonel.htm

9. www.yoursurgery.com/ProcedureDetails.cfm?BR=3&Proc=36

10. American Cancer Society. Modelled data: cancer facts and figures, 2006.

11. Worldwide Cancer Mortality Statistics, ASR(w) for Annual Mortality per 100 000 by sex and age group, http://www.depd. iarc.fr/who/menu.htm

12. Yancik, R. and Ries, L.A., 1994. Cancer in older persons. Magnitude of the problem: how do we apply what we know? Cancer, 74 (7 Suppl), 1995–2003.

13. Silliman, R.A. and Baeke, P., 1998. Breast cancer in the older woman. In: Balducci, L., Ersher, WB. and Lyman, G.H. Comprehensive geriatric oncology. Amsterdam: Harwood.

14. Welch, H.G., Albertson, P.O., Nease, R.E, Bubolz, T.A. and Wasson, J.H., 1996. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med, 124, 577–584.

15. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Ben-bella Books.

16. Dobson, R., 2006. Breast cancer incidence rises in contaminated areas 10 years after explosion at Chernobyl reactor. BMJ, 332, 567.

17. Jakes, R.W and others, 2002. Mammographie parenchymal patterns and self-reported soy intake in Singapore Chinese women. Cancer Epidemiological Biomarkers Prev, 11, 608–613.

18. www.cancer.org;

www.cancer.org/docroot/CRI/content/CRl_2_4_2X_What_ are_the_risk_factors_for_breast_cancer_5.asp

19. Dobson, R., 2006. Diethylstilbestrol increase risk of breast cancer death. BMJ, 333, 64.

20. www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_ are_the_risk_factor s_for_male_breast_cancer_28.asp

21. www.dep.iarc.fr/globocan/database.pdf

22. WHO International Agency for Research on Cancer (IARC), IARC Cancer Epidemiology Database. GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide. Ferlay, J., Bray, F., Piesci, P. and Parkin, D.M. (editors), www.dep.iarc. fr/globocan/ database.pdf

23. Campbell, T.C., and Junshi, C., 1994. Diet and chronic degenerative disease perspectives from China. American Journal of Clinical Nutrition, 59, Suppl., 11 535-11 615.

24. Jakes, Rupert W, Duffy, Stephen Ж., Ng, Fook-Cheong, Gao, Fei, Ng, Eng-Hen, Seow, Adeline, Lee, Hin-Peng and Yu, Mimi C., 2002. Mammographic Parenchymal Patterns and Self-re-ported Soy Intake in Singapore Chinese Women. Cancer Epidemiology Biomarkers & Prevention, 11, 608–613.

25. Statistical Abstracts of the US, 1994 edition.

26. T. Colin Campbell, quoted in www.milksucks.com/osteo.html; Robbins, John, 1987, A Diet for a New America. Stillpoint Publishing; McDougall, John, 2000. The McDougall Program for Women; Plant, Jane and Tidey, Gill, 2003. Understanding, Preventing and Overcoming Osteoporosis. Virgin Books.

27. IARC Cancer Epidemiology Database. GLOBOCAN 2000, Cancer incidence, mortality and prevalence worldwide. Ferlay, J., Bray, F., Piesci, P., and Parkin, D.M. (editors), www.dep.iarc.fr/globocan/ database.pdf

28. Frassetto, L.A., Todd, K.M., Morris, R.C., Jr and Sebastian, A., 2000. Worldwide incidence of hip fracture in elderly women: relation to consumption of animal and vegetable food s. Journal of Gerontology: Medical Sciences, 55 A. 10, M585-M592.

Дополнение к главе 4

1. Jakes, Rupert W, Duffy, Stephen W, Ng, Fook-Cheong, Gao, Fei, Ng, Eng-Hen, Scow, Adeline, Lee, Hin-Peng and Yu, Mimi C., 2002. Mammographic Parenchymal Patterns and Self-re-ported Soy Intake in Singapore Chinese Women. Cancer Epidemiology Biomarkers & Prevention, 11, 608–613.

2. Pringle, H., 1998. Neolithic agriculture: reading the signs of ancient animal domestication. Science. 282, 1448.

3. Thomas M and others, 2007, Proc Nat Acad Sei.

4. Latham, M.C., 1997. Human nutrition in the developing world, Rome, 1997. FAO Food and Nutrition Series № 29, Cornell University, Ithaca, NY.

5. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

6. AbuGhazaleh, A.A. and others, 2004. CLA increases in milk when cows fed fish meal and extruded soybeans for an extended period of tim t. Journal of Dairy Science, 87 (6), 1758–1766.

7. Petit, H.V., 2002. Digestion, milk production, milk composition, and blood composition of dairy cows fed whole flax seed. Journal of Dairy Science, 85 (6), 1482–1490.

8. Wahle, K.W and others, 2004. CLAs: are they beneficial or detrimental to health? Progress in Lipid Research, 43 (6), 553–587.

9. Willett, WC, and Stampfer, M.J., 2007. Rebuilding the food pyramid. Scientific American, Special edition on diet and health, February 2007, 12–21.

10. The Royal Society, 2000. Endocrine-disrupting chemicals. Document 06/00. The Royal Society.

11. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

12. Qin, L.Q. and others, 2004. Estrogen: one of the risk factors in milk for prostate cancer. Medical Hypotheses, 62 (1), 133–142.

13. Hartman, S. and others, 1998. Natural occurrence of steroid hormones in food. Food Chemistry, 62, 7-20.

14. Buder, J., 2006. White lies. Vegetarian and Vegan Foundation.

15. Ganmaa, D. and Sato, A., 2005. Possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Medical Hypotheses, 65 (6), 1028–1037.

16. DEFRA, 2005. Agriculture in the UK, 2004. Norwich, UK: HMSO.

17. Campbell, T.C. and Junshi, C., 1994. Diet and chronic degen erative disease perspectives from China. Am J Clin Nutr, 59, Suppl., 11 535-11 615.

18. Charatan, Fred, 2003. Book Review: Fat Land: How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

19. Charatan, Fred, 2003. Book Review: Fat Land: How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

20. Charatan, Fred, 2003. Book Review; Fat Land; How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

21. Grosvenor, C.E. and others, 1992. Hormones and growth factors in milk. Endocrine Reviews, 14 (6), 710–728.

22. http://www.dhn.csiro.au/crctissue.html

23. http://www.13.waisays.com/cancer2.htm

24. le Huerou-Luron, I. and others, 1998. Source of dietary protein influences kinetics of plasma gut regulatory peptide concentration to feeding in preruminant calves. Comparative Biochemistry and Physiology: A – Molecular and Integrative Physiology, 119 (3), 817–824.

25. Koldovski, O. and others, 1995. Milk-borne hormones: possible tools of communication between mother and suckling. Physiological Research, 1995, 44 (6), 349–351, Koldovsky, O. and others, 1994. Hormonally active peptides in human milk. Acta Paediatrica Suppl., 402, 89–93; Lehy,T. and others, 1990. Promoting effect of bombesin on the cell proliferation in the rat endocrine pancreas during the early post natal period. Regulatory Peptides, 27 (1), 87–96; Pollack, P.F., 1989. Effects of enterally– and parenterally-administrated bombesin on intestinal luminal tryptic activity and protein in the suckling rat. Ex-perienta, 45 (4), 385–388; Lazarus, L.H. and others, 1986. An immunoreactive peptide in milk contains bombesin-like bioactivity. Experienta, 42 (7), 822–823; Jahnke, G.D. and others, 1984. A bombesin immunoreactive peptide in milk. Proc Natl Acad Sei USA, 81 (2), 578–582.

26. Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides in human milk. Am J ClinNutr, 51 (6), 985–990.

27. Burns, D.M. and others, 1999. Breast cancer cell-associated en-dopeptidase EC24.11 modulates proliferative response to bombesin, British Journal of Cancer, 79 (2), 214–220; Bold, R.J, and others, 1998. Bombesin stimulates in vitro growth of human breast cancer independent of estrogen receptor status. Anticancer Research, 18 (16A), 4051–4056; Miyazaki, M. and others, 1998. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-11 and RC-3095. European Journal of Cancer, 34 (5), 710–717; Nelson, J, and others,

1991. Bombesin stimulates proliferation of human breast cancer cells in culture. Br. J. Cancer, 63 (6), 933–936; Giacchetti, S. and others, 1990. Characterization, in some human breast can-

cer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer, 46 (2), 293–298; Weber, C.J. and others, 1989. Gastrin-releasing peptide, calcitonin gene-related peptide, and calcitonin-like immu-no-reactivity in human breast cyst fluid and gastrin-releasing peptide-like immunoreactivity in human breast carcinoma cell lines. Surgery, (6), 1134–1139 (disc. 1139–1140).

28. Markwalder, R. and others, 1999. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Research, 59 (5), 1152–1159; Festuccia, C. and others, 1998. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int. J. Cancer, 75 (3); 418–431: Krongrad, A. and others, 1997. Endopeptidase 24.11 activity in the human prostate cancer cell lines LNCaP and PPC-1. Urological Research, 25 (2), 113–116; Jungwirth, A. and others, 1997. LHRH antagonist Cetrolix (SB-75) and bombesin-antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Larran, J. and others, 1996. In vitro characterization of bombesin and calcitonin on the proliferation of PC3, DK145 and LNCaP cancer prostatic cell lines. International Journal of Developmental Biology, 1996 (Suppl. 1), 275S-276S; Aprickian, A.G. and others, 1996. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostatic cancer cells. Journal of Molecular Endocrinology, 16 (3), 297–306; Bologna, M. and others, 1989. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer, 63 (9), 1714–1720; Wasilenko, WJ. and others, 1996. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer, 68 (2), 259–264.

29. Takeyama, M. and others, 1989. Enzyme immunoassae of gastrin-releasing, peptide (GRP)-like immunoreactivity in milk. Int J Pept Protein Res, 34 (1), 70–74.

30. Ducroc, R. and others, 1995. Immunoreactive substance P and calcitonin-gene-related peptide (CGRP) in rat milk and in human milk and infant formula’s. Am J Clin Nutr, 62 (3), 554–558.

31. Lembeck, F. and others, 1979. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Arch Pharmacol, 310 (2), 175–183.

32. Khare, V K. and others, 1998. The neuropeptide/mast cell secretagogue substance F is expressed in cutaneous melano-cyticlesions. Journal of Cutaneous Pathology, 25 (1), 2-10.

33. Ducroc, R. and others, 1995. Immunoreactive substance P and calcitonin-gene-related peptide (CGRP) in rat milk and in human milk and infant formula’s. Am J Clin Nutr, 62 (3), 554–558.

34. Faulkner, A., 1998. Insulin-like growth factor 1 concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions, 26 (4), 386; Silanikove, N. and others, 1998. Metabolic and productive response of dairy cows to increased ion supplementation at early lactation in warm weather. Journal of Dairy Research, 65 (4), 529–543; Ginjala, V. and others, 1998. Determination of transforming growth factor-beta 1 (TGF-beta 1) and insulin-like growth factor-1 (IGF-1) in bovine colostreum samples. Journal of Immunoassay, 19 (2–3), 195–207; Schober, D.A. and others, 1990. Perinatal expression of type 1 IGF receptors in porcine small intestine. Endocrinology, 126 (2), 1125–1132.

35. Rao, R.K. and others, 1998. Luminal stability of insulin-like growth factor-1 and -2 in developing rat gastrointestinal tract. Journal of Pediatric Gastroenterology and Nutrition, 26 (2), 179–185.

36. Parisot, J.P. and others, 1999. Altered expression of the insulinlike growth factor-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer, 79 (5–6), 693–700; Sciacca, L. and others, 1999. Insulin receptor activation by insulin-like growth factor-2 in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene, 18 (15), 2471–2479; Grothey, A. and others, 1999. The role of insuline-like growth factor and its receptor in cell growth transformation, apopto-sis, and chemoresistance In solid tumor s. Journal of Cancer Research and Clinical Oncology, 125 (3–4), 166–173; Perks, C. M. and others, 1999. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of insulin-like growth factor-1 (IGF-1) in human breast cancer cell lines. Br J Cancer, 79 (5–6), 701–706; de Cupis, A. and others, 1998. Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line; comparison between early and late cultures. In Vitro Cellular and Developmental Biology – Animal, 34 (10), 836–843; Kobari, M. and others, 1998. The inhibitory effect of an epidermal growth factor receptor specific tyrokinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF-1. International Journal of Pancreatology, 24

(2), 85–95; Gooch, J.L. and others, 1998. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res, 58 (18), 4199–4205; Choki, I. and others, 1998. Osteobiast-derived growth factors enhance adriamycin-cytos-tasis of MCF-7 human breast cancer cells. AnticancerRes, 18 (16A), 4213–4224; Jackson, J.G. and others, 1998, Insulin receptor substrate-1 is the predominant signalling molecule activated by insulin-like growth factor-1, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. Journal of Biological Chemistry, 273 (16), 9994-10 003; Westley,

B.R. and others, 1998. Interactions between the oestrogen and IGF signalling pathways in the control of breast epithelial cell proliferation. Biochemical Society Symposium, 63, 35–44; Sur-macz, E. and others, 1995. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clinical Cancer Research, 1 (11), 1429–1436.

37. Untersasser, G. and others, 1999. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Experimental Gerontology, 34 (2), 275–287; Xu, Z.D., 1999. Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-2 ribonucleic acid in vitro and in prostate cancer cells. Endocrinology, 140 (5), 2134–2144; Marelli, M.M. and others, 1999. Luteinizing hormone-releasing hormone agonists interfere with the antagonic activity of the insulin-like growth factor system in androgen-dependent prostate cancer cells. Endocrinology, 140 (1), 329–334; Larnharzi, N. and others, 1998. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DY-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor-2 in tumors. Proc Natl Acad Sei USA, 95 (15), 8864–8868; Wang, Y.Z. and others, 1998. Sex hormone-induced prostatic carcinogenesis in the noble rat; the role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of cancer. Prostate, 35 (3), 165–177.

38. He, Y., 1999. Comment on the Association between Insulin-Like Growth Factor-1 (IGF-I) and Bone Mineral Density: Further Evidence Linking IGF-I to Breast Cancer Risk. Journal of Cellular Endocrinology and Metabolism, 84, 1760.

39. Perks, C. M. and Holly, J.M.P., 2000, Insulin-Like Growth Factor Binding Proteins (IGFBPs) in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 5, 75–84.

40. Murphy, M.S. and others, 1998. Growth factors and the gastrointestinal tract. Nutrition, 14 (10), 771–774; Buts, J.F., 1998, Bioactive factors in milk, (in French.) Archives de Pediatrie, 5 (3), 298–306.

41. Shen, WH. and others, 1998. Stability and distribution of orally administered epidermal growth factor in neonatal pigs. Life Sciences, 63 (10), 809–820; Rao, R.K. and others, 1998. Bovine milk inhibits proteolytic degradation of epidermal growth factor in human gastric and duodenal lumen. Peptides, 19 (3), 495–504; McCuskey, R.S. and others, 1997. Effect of milk-borne epidermal growth factor on the hepatic microcirculation and Kupfer cell function in suckling rats. Biology of the Neonate, 7 (3), 202–206; Oguchi, S. and others, 1997. Growth factors in breast milk and their effect on gastrointestinal development. Chang Hua Min Kuo Hsiao Ehr Ко I Hsuek Tsa Chih, 38 (5), 332–337.

42. Salomon, D.S. and others, 1999. Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bioessays, 21 (1), 61–70; Chou, YC. and others, 1999. Induction of mammary carcinomas by N-meth-yl-N-nitrosurea in ovariectomized rats treated with epidermal growth factor. Carcinogenesis, 20 (4), 677–684; Kurtz, A. and

others, 1998. Local control of mammary gland differentiation: mammary-derived growth inhibitor and pleiotrophin. Biochemical Society Symposium, 63, 51–69; Taylor, M.R. and others, 1997. Lactadherin (formerly BA46); a membrane-associat-ed gycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA and Cell Biology, 16 (7), 861–869.

43. Zhau, H.J. and others, 1996. Androgen-depressed phenotype in human prostate cancer. Proc. Natl. Acad. Sei. U.S.A., 93 (26), 15 152-15 157.

44. Thornburg, W. and others, 1984. Gastrointestinal absorption of epidermal growth factor in suckling rats. American Journal of Physiology, 246, G80—G85.

45. www.prostatepointers.org/cmyers/pf0696.html

46. Gaull, G.E. and others, 1985. Significance of growth modulators in human milk. Pediatrics, 75 (2), 142–145.

47. Delgrange, E. and others, 1997. Sex related differences in the growth of prolacrinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism. 82 (7), 2102–2107.

48. Vonderhaar, B.K., 1998, Prolactin: The forgotten hormone of human breast cancer. Pharmacology and Therapeutics, 79 (2), 169–178; Das, R. and others; 1996. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene, 13 (6), 1139–1145; Mershon, J, and others, 1995. Prolactin is a local growth factor in rat mammary tumors. Endocrinology, 136 (8), 3619–3623; Ginsberg, E. and others, 1995. Prolactin secretion by human breast cancer cells. Cancer Res, 55 (12), 2591–2595; Fuh, G. and others, 1995. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem, 270 (22), 13 133-13 137.

49. Leav, I. and others, 1999. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. American Journal of Pathology, 154 (3), 863–870; Horti, J. and others, 1998. A phase 2 study of bromocriptine in patients with androgen-independent prostate cancer. Oncology Reports, 5 (4), 893–896; Franklin, R.B. and others, 1997. Prolactin regulation of mitochondrial aspartate aminotransferase and proteinkinase С Molecular and Cellular Endocrinology, 127 (1), 19–25; Janssen, T. and others, 1996. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer, 77 (1), 144–149; Janssen, T. and others, 1995. Organ culture of human tissue as study model of hormonal and pharmacological regulation of benign prostatic hyperplasia and of prostatic cancer, (frans) Acta Urol Belg, 63 (1), 7-14; Oliver, R.T. and others, 1995. New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy. Eur J Cancer, 31A (6), 859–860; Rana, A. and others, 1995. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer, 31A (6), 871–875.

50. Hinuma, S. and others, 1998. A prolactin-releasing peptide in the brain. Nature, 393 (6682), 272–276.

51. Smith, S.S. and others, 1986. Presence of luteinising hormone-releasing hormone (LHRH) in milk. Endocrinol Exp., 2 °C2-3), 147–153; Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J.Nu-tr., 119 (II), 1543–1551; Nair, R.M. and others, 1987. Studies on LHRH and physiological fluid amino acids in human colos-treum and milk. Endocrinolologia Experimentalise 21 (1), 23–30.

52. White, M.E. and others, 1986. Milk progesterone concentrations following simultaneous administration of buserelin and cloprostenol in cattle with normal corporal lutea. Canadian Journal of Veterinary Research, 50 (2), 285–286; Dinsmore, R.P. and others, 1989. Effect of gonadotropin-releasing hormone on clinical response and fertility in cows with cystyic ovaries, as related to milk progesterone concentration and days after partarition. Journal of the American Veterinary Medical Association, 195 (3), 327–330.

53. Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides in human milk. Am J Clin Nutr, 51 (6), 985–990.

54. Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides inhuman milk. Am J Clin Nutr, 51 (6), 985–990.

55. Flood, J.F. and others, 199L Increased food intake by neuropeptide Y is due to an increased motivation to eat. Peptides, 12 (6), 1329–1332.

56. Amarant, T. and others, 1982. Luteinising hormone-releasing hormone and thyrotropin-releasing hormone in human and bovine milk. European Journal of Biochemistry, 127 (3), 647–650; Baram, T and others, 1977. Gonadotropin-releasing hormone in milk. Science, 198 (4314), 300–302.

57. Koike, K. and others, 1997. The pituitary folliculo-stellate cell line TtT/GF augments basal and TRH-inducedprolactin secretion by GH3 cells. Life Sei, 61 (25), 2491–2497; Tyson, J.E. and others, 1975. The influence of prolactine secretion on human lactation./ Clin Endocrinol Met ah, 40 (5), 764–773.

58. Grochowska, R. and others, 1999. Stimulated growth hormone (GH) release in Friesian cattle with respect to GH genotypes. Reproduction Nutrition Development, 39 (2), 171–180; Bourne, R.A. and others, 1977. Serum growth hormone concentrations after growth hormone or thyroid-releasing hormone in cows. Journal of Dairy Science, 60 (10), 1629–1635.

59. Chomczinsky, E and others, 1993. Stimulatory effect of thyroid hormone on growth hormone gene expression in a human pituitary cell line. / Clin Endocrinol Metah, 77 (1), 281–285; Reynolds, A.M., 1991. The effects of chronic exposure to supra physiological concentrations of 3,5,3-triiodo-L-thyronine (T3) on cultured GC cell s. Journal of Cellular. Physiology, 149 (3), 544–547.

60. Tenore, A. and others, 1980. Thyroidal response to peroral TSH in suckling and weaned rats. American Journal of Physiology, 238 (5), E428-430.

61. Slebodzinski, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5’-monodiodinase (5’-MD) in mare’s milk from partarition to 21 days post-partum. Reproduction Nutrition Development, 38 (3), 235–244.

62. Fujimoto, N. and others, 1997. Upregulation of the estrogen receptor by triiodothyronine in rat pituitary cell lines. Journal of Steroid Biochemistry and Molecular Biology, 61 (1–2), 79–85.

63. Koldovsky, О., 1989. Search for the role of milk borne biologically active peptides for the suckling. J Nutr, 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk, (in French.) Arch Pediatr, 5 (3), 298–306.

64. Faulkner, A., 1998. Insulin-like growth factor concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions, 26 (4), S386; Baldini, E. and others, 1994. In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma. Journal of Biological Regulators and Homeostatic Agents, 8 (4), 113–116; Scheven, B.A. and others, 1991. Effects of recombinant human insulin-like growth factor-1 and -2 (IGF) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regulation, 1 (4), 160–167; Hodate, K. and others, 1990, Plasma growth hormone, insuline-like growth factor-1, and milk production response to exogenous human growth hormone-releasing factor analogs in dairy cows. Endocrinolo-gia Japonica, 37 (2), 261–273.

65. Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J Nutr, 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk, (in French.) Arch Pediatr, 5 (3), 298–306.

66. Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. / Pediatr Gastroenterol Nutr, 6 (3), 460–465; Ehman, R. and others, 1985. Bombesin, neurotensin and pro-gamma-mel-anotropin in immunoreactants in human milk. Regulatory Peptides, 10 (2–3), 99-105.

67. Shutt, D.A. and others, 1985. Comparison of total and free cortisol in bovine serum and milk colostreum. J Dairy Set, 68 (7), 1832–1834.

68. Vaarala, O. and others, 1998. Cow milk feeding induces antibodies to insulin in children – a link: between cow milk and insulin-dependent diabetes mellitus? Scandinavian Journal of Immunology 47 (2), 131–135; Slebodzinsky, A.B. and others,

1998. Triiodothyronine (T3), insulin and characteristics of 5’-monodiodinase (5’-MD) in mare’s milk from partarition to 21

days post-partum. Reprod Nutr Dev, 38 (3), 235–244; We-strom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J Pediatr Gastroenterol Nutr, 6 (3), 460–465.

69. Ferrando, T. and others, 1990. Beta-endorphin-like and alpha-MSH-like immunoreactivities in human milk. Life Sei, 47 (7), 633–635.

70. http://www.13.waisays.com/cancer2.htm; Newcomb, P.A. and Egan, K.M., 2006. Dairy food and ovarian cancer risk. The Lancet, March 2006, 797–799; Stang, A. and others, 2006. Adolescent milk fat and galactose consumption and testicular germ cell cancer. Cancer Epidemiology and Biomarkers Prevention, 15,2189–2195.

71. Maruuchi, T. and others, 1998. Effects of gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo .Japanese Journal of Cancer Research, 89 (9), 977–983; Kuroda, H. and others, 1998. Human chorionic gonadotrophin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of IGF-1 by hCG. Int J Cancer, 76 (4), 571–578; Kurbacher, C.M. and others, 1995. Influence of luteinising hormone on cell growth and С A 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biology, 16 (6), 374–384; Manetta, A. and others, 1995. Inhibition of growth of human ovarian cancer in nude mice by luteinising hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertility and Sterility, 63 (2), 282–287.

72. Reiter, E. and others, 1999. Effects of pituitary hormones on the prostate. Prostate, 38 (2), 159–165; Lamharzi, N. and others, 1998. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-2 in tumors. Regulatory Peptides, 77 (113), 185–192; Jungwirth, A. and others, 1997. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-2 inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Maeza-wa, H. and others, 1997. Potentiating effect of buserelin ace-täte, an LHRH agonist on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Int J Urol,

4 (4), 411–416; Using, АЖ and others, 1993. Serological precursors of cancer serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev, 2 (1), 27–32; Garde, S. and others, 1993. Effect of prostatic inhibiting peptide on prostate cancer cell growth in vitro and in vivo. Prostate, 7 (2), 183–194.

73. Bosland, M.C., 1996. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Progress in Clinical and Biological Research, 394, 309–352.

74. Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control, 1,281–284.

75. http://www.who.int

76. Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control,, 1.281–284.

77. http://www.who.int

78. http://www.13.waisays.com/cancer2.htm

79. Underwood, L.E., D’Ercole, J.A. and Van Wyk, J.J., 1980. So-matomedin-C and the assessment of growth. Ped ClinN Amer,

27, 4, 771–782, and Perdue, J.E 1984. Chemistry, structure and function of insulin-like growth factors and their receptors: a review. Can J Вiochem Cell Bio, 62, 1237–1245.

80. http://vw.com/healthnews/milk.html

81. Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

82. Lonning, Per Eystein, 2003. IGF-I and breast cancer. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

83. Yee, Doug, 2003. Targeting the IGF system for anti-tumour therapy. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

84. Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled ‘Biology of IGF-I; its interaction with insulin in health and malignant states’.

85. Holly, Jeff, 1998. Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet, 351, 9113, 9 May, 1373–1375.

86. Chan, J.M., Stampfer, M.J., Giovannucci, E. and others, 1998. Plasma insulin-like growth factor-I and prostate cancer risk; a prospective study. Science, 279, 563–566; Harman, S.M., Metter, E.J., Blackmail, M.R., Landis, EK. and Carter, H.B., 2000. Serum levels of insulin-type growth factor 1 (IGF-I), IGF II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab, 85, 4258–4265; Stattin, E and nine others, 2000. Flasma insulin-like growth factor-I insulin-like growth-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst, 92, 1910–1917; Chokkalingam, A.F, and 12 others, 2001. Insulinlike growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev, 10, 421–427; Chan, J.M., Stampfer, M.J., Ma, J. and others, 2002. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst, 94, 1099–1106; Mantzoros, C.S., Tzonou, A., Signorello, L.B. and others, 1997. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer, 76, 1115–1118; Wolk, A., Mantzoros, C.S., Anders-son, S.O. and others, 1998. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst, 90, 911–915; Holly, J.M.E, Gunnell, D.J. and Davey Smith., G, 1999. Growth hormone, IGF-1 and cancer. Less intervention. Less intervention to avoid cancer? More intervention to prevent cancer. J Endocrinol, 162, 321–330.

87. Yu, H. and others, 1999. Flasma levels of IGF-I and lung cancer risk, Journal of the National Cancer Institute, 91, 151–156.

88. Ma, J. and others, 2001. Milk intake, circulating levels of IGF-1 and risk of colorectal cancer in men. Journal of the National Cancer Institute, 93 (17), 1330–1336.

89. LeRoith, D. and others, 1995. The role of the IGF-I receptor in cancer. Annals of the New York Academy of Sciences, 766, 402–408; Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

90. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Ben-bella Books.

91. Bradford Hill, A., 1965. The environment and disease; association or causation? Proceedings of the Royal Society of Medicine,

58, 295–300.

92. Holly, J.M.P., Gunnell, D.J. and Davey Smith, G., 1999. Growth hormone, IGF-I and cancer. Less intervention. Less intervention to avoid cancer? More intervention to prevent cancer. J Endocrinol, 162, 321–330.

93. Bobbins, John, 1987. A Diet for a New America, Stillpoint Publishing.

94. www.dhn.csiro-au/crctissue.html

95. Xian, C., 1995. Degradation of IGF-I in the Adult Rat Gastrointestinal Tract is limited by a Specific Antiserum of the Dietary Protein Casein .Journal of Endocrinology, 146, 2, 1 August, 215; Thornburg, Ж and others, 1984. Gastrointestinal absorption of epidermal growth factor in suckling rats. American Journal of Physiology, 246, G80-G85.

96. The European Commission. Health and Consumer Protection. Scientific Committee on Veterinary Measures relating to Public Health – Outcome of discussions.

http://europa.eu.int/comm/dg24/health/ sc/scv/ outl9_en.html

97. Allen, N.K, and others, 2000, Hormones and Diet; Low Insulin-like Growth Factor-1 but Normal Bioavailable Androgens in Vegan Men. Brit J Cane, 83 (1), 95–97.

98. Steinman, G., 2006. Can the chance of having twins be modified by diet? The Lancet, 367 (9521), 1461–1462.

99. Norat and others, 2007. Diet, serum IGF-1 and IGF-BP3 in European women. European Journal of Clinical Nutrition, 61, 91–98.

100. The European Commission. Health and Consumer Protection. Scientific Committee on Veterinary Measures relating to Public Health – Outcome of discussions. http://europa.eu.int/comm/dg24/health/sc/scv/outl9_ en.html

101. Heaney, R.P. and others, 1999. Dietary changes favourably affect bone remodelling in older adults, Journal of the American Dietetic Association, 99 (10), 1228–1233.

102. Gunnell, D.L. and 10 others, 2003. Are diet – prostate-can-cer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. British Journal of Cancer, 88, 1682–1686.

103. World Cancer Research Fund, 1997. Food, nutrition and the prevention of cancer: a global perspective. Washington, DC: American Institute of Cancer Research.

104. Allen, N.E., Appleby, P.N., Davey, G. K. and Key, T.J., 2000. Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men. Br J Cancer. 83, 95–97.

105. Yaker, S. and others, 2005. The role of the growth hormone/ IGF axis in tumour growth and progression: lessons from animal models. Cytokine and Growth Factor Reviews, 16 (4–5), 407–420; Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

106. Mannisto, S. and others, 1999. Diet and the risk of breast cancer in a case control study: does the threat of disease have an influence on recall bias? Journal of Clinical Epidemiology, 52 (5), 429–439; Outwater, J.L. and others, 1997. Dairy products and breast cancer: the IGF-1, estrogen and bGH hypothesis. Medical Hypotheses, 48 (6), 453–461; Gaard, M. and others, 1995. Dietary fat and the risk of breast cancer: a prospective study of 25 892 Norwegian women. Int J Cancer, 63 (1), 13–17; Decarli, A. and others, 1986, Environmental factors and cancer mortality in Italy: correlational exercise. Oncology, 43 (2), 116–126; Rose, D.P. and others, 1986. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer, 58 (11), 2363–2371; Shimada, A. and others, Ecological approach to the eating habits and the cancer mortality of Brazilian people, (in het Japans) Can No Rinsho, 32 (6), 631–640; La Vecchia, C. and others, 1986, Age at first birth, dietary practises and breast cancer mortality in various Italian regions. Oncology, 43 (1), 1–6; Talamini, R. and others, 1984. Social factors, diet and breast cancer in a northern Italian population. Br J Cancer. 49 (6), 723–729.

107. Rose, D. P. and others, 1986. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer, 58 (11), 2363–2371.

108. Schuurman, A.G. and others, 1999, Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study, Br J Cancer, 80 (7), 1107–1113; Giovannucci, E., 1999. Nutritional factors in human cancers. Advances in Experimental Medicine and Biology, 472, 29–42; Giovanucci, E., 1998. Dietary influences of 1,25 (OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes and Control, 9 (6), 567–582; Willet, WC., 1997. Nutrition and Cancer. Sa-lud Publica de Mexico, 39 (4), 298–309; De Stefani, E. and others, 1995, Tobacco, alcohol, diet and risk of prostate cancer. Tumori, 81 (5), 315–320; Le Marchand, L. and others, 1994. Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology, 5 (3), 276–282; Talamini, R. and others, 1992. Diet and prostate cancer: a case control study in northern Italy. Nutrition and Cancer, 18 (3), 277–286; La Vecchia, C. and others, 1991. Dairy products and the risk of prostatic cancer. Oncology, 48 (5), 406–410; Mett-lin, C. and others, 1989. Beta-carotene and animal fats and their relationship to prostate cancer risk. A case control study. Cancer, 64 (3), 605–612; Snowdon, D.A., 1988. Animal product consumption and mortality because of all causes combined, coronary heart disease, stroke, diabetes, and cancer in Seventh-day Adventists. Am J Clin Nutr, 48 (3 Suppl), 739–748; Talamini, R. and others, 1986. Nutrition, social factors, and prostate cancer in a northern Italian population. Br J Cancer, 53 (6), 817–821; Rose, D.P. and others, 1986. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer, 58 (11), 2263–2271.

109. Newby, JA. and Howard, 2006. Environmental influences in cancer aetiology, 2006, 1-59.

110. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

111. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

112. Lawrence R., 1994. Breastfeeding – A Guide to the Medical Profession, Fourth edition. Mossby.

113. Holly, J.M.P., Gunnell, D.J. and Davey Smith, G., 1999. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol, 162, 321–330.

114. Giudice, L.A., 1992. Insulin-like growth factors and ovarian follicular development. Endocrine Reviews, 13, 641–669.

115. Westlev, B.R. and May, F.E.B., 1994. Role of insulin-like growth factors in steroid modulated proliferation. Journal of Steroid Bioehemistry and Molecular Biology, 51, 1–9; Marcelli, M., Haidacher, S.J., Plymate, S.R. and Birnbaum, R.S., 1995. Altered growth and insulin-like growth factor-binding protein-3 production in PC-3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology, 136, 1040–1048.

116. Holly, J.M.P., Gunnell, D.J. and Davey Smith, G., 1999. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol, 162, 321–330.

117. Bernstein, I. and Ross, R.K., 1993. Endogenous hormones and breast cancer risk. Epidemiol Res, 15, 48–65; Pike, M.C. and others, 1993. Estrogens, progestogens, normal breast proliferation and breast cancer risk. Epidemiol Reviews, 15, 17–35.

118. Bocchinfuso, WF. and others, 2000. Induction of mammary gland development in estrogen receptor-alpha knoclout mice. Endocrinology; 141; 2983–2994; Attwood, C.S. and others,

2000. Progesterone induces side-branching of the ductal epithelium in the mammary glands of prepubertalmice. J Endocrinology, 167, 39–52.

119. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Healths. Benbella Books.

120. www.breakthrough.org.uk

121. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Benbella Books.

122. Cramer, D.W and others, 1989. Galactose consumption and metabolism in relation to the risk of ovarian cancer Lancet, 2, 66–71.

123. Fairfield and others, 2004. A prospective study of dietary lactose and ovarian cancer. Int J of Cancer, 110 (2), 271–277.

124. Larsson, S.C. and others, 2004. Milk and lactose intakes and ovarian cancer risk. In the Swedish Mammography Cohort. Amer J Clinical Nutrition, 80 (5), 1353–1357.

125. Larsson, S.C. and others, 2005. Milk, milk products and lactose intake and ovarian cancer risk: a meta analysis of epidemiological studies. Int J of Cancer.

126. Ganmaa, D. and Sato, A., 2005. Possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Medical Hypotheses, 65 (6), 1028–1037.

127. Hartman, S. and others, 1998. Natural occurrence of steroid hormones in food. Food Chemistry, 62, 7-20; Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

128. Plant, Jane and Tidey, Gill, 2005. Eating for Better Health. Virgin Books.

129. Bahna, S,L., 1987. Milk allergy in infancy. Ann Allergy. 59, 131.

130. Dunea, G., 1982. Beyond the Etheric. BMJ, 285, 428–429.

131. Kretchmer, N., 1981. The Significance of lactose intolerance. In: Paige, D.M. and Bayless, T.M., Editors., Lactose Digestion: Clinical and nutritional implications. Johns Hopkins University Press.

132. http://www.fda.gov/fdac/features/2OOV4 01_food.html

133. http://www.ifst.org/hottopl9.htm

134. Taylor, S.L., 1992. Chemistry and detection of food allergens. Food Technology, 46 (5), 146–152.

135. Saarinen, K.N. and others, 2005. Clinical course and prognosis of cow’s milk allergy are dependent on milk-specific IgE statu s. Journal of Allergy and Clinical immunology, 136 (4), 869–875.

136. http://www.ifst.org/hottopl9.htm

137. Martin, Peter, 2002. Milk: Nectar or poison? Sunday Times Magazine, July 21. 2002.

138. Thorsdottir, I. and Ramel, A., 2003. Dietary intake of 10– to 16-year-old children and adolescents in Central and Northern Europe and association with the incidence of type-1 diabetes. Annals of Nutrition and Metabolism, 47 (6), 267–275.

139. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Benbella Books.

140. ТВ bacteria found in treated milk. Sunday Times, 20 February, 2000.

141. Bull, T.J. and others, 2003. Detection and verification of My-cobactenum avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without

Crohn’s disease, Journal of Clinical Microbiology. 41 (7), 2915–2923.

142. Millar, D. and others, 1996. IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows’ milk in England and Wales. Applied and Environmental Microbiology, 62 (9), 3446–3452.

143. Pickup, R.W and others, 2005. MAP in the catchment area and water of the River Taff in South Wales, UK and its potential relationship to clustering of Crohn’s disease cases in the city of Cardiff. Applied and Environmental Microbiology, 71 (4), 2130–2139.

144. FSA/SE, 2001. Task force on E.coli 0157.

www.f ood. gov.uk/ mnltimedia/pdfs/ecolitaskfinreport.pdf

145. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

146. Plant, Jane and Tidey, Gill, 2003. Understanding, Preventing and Overcoming Osteoporosis. London: Virgin Books.

147. Robbins, John, 1987. A Diet for a New America. Stillpoint Publishing.

148. Hegsted D.M., 1986. Calcium and osteoporosis. J Nutr, 116, 2316–2319.

149. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Benbella Books.

150. Ademamowo, C.A. and others, 2005. High-school dietarv dairy intake and teenage acne. Journal of the American Academy of Dermatology, 52 (2), 207–214.

151. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

152. Toohey, M.L., and others, 1998. Cardiovascular disease risk factors are lower in African-American vegans compared to lacto-ovo-vegetarians. Journal of the American College of Nutrition, 17 (5), 425–434.

153. Park, M. and others, 2005. Consumption of milk and calcium in mid-life and the future risk of Parkinson disease. Neurology, 64, 1047–1051.

Дополнение к главе 5

1. World Cancer Research Fund and American Institute for Cancer Research. 1997. Food, Nutrition and the Prevention of Cancer: a Global Perspective. Washington DC: American Institute for Cancer Research (http://www.aicr.org/report2.htm).

2. http://www.pcrm.org/health/Dairy_and_Prostate_Cancer/ d-p-article.html

3. Plant, Jane and Tidey, Gill, 2002. The Plant Programme. Paperback edition. Virgin Books; Plant, Jane and Tidey, Gill, 2003. Understanding, Preventing and Overcoming Osteporosis. Virgin Books; Plant, Jane, 2004, updated 2007. Prostate Cancer: Understand, Prevent and Overcome. Virgin Books; Plant, Jane and Tidey, Gill, 2005. Eating for Better Health. Virgin Books.

4. Smith-Warner, S.A. and Giovannucci, E., 1999. Fruit and vegetable intake and cancer. In: Heber, D., Blackburn, G.L. and Go, V.L.W, editors. Nutritional oncology. San Diego: Academic Press. 153–183.

5. American Institute for Cancer Research, 2000. Press Release (August 31, 2000) from the AICR Annual Research Conference 2000: New Methods in Clinical Trials Lending New Insights on Diet-cancer Connection, Expert Says.

6. National Cattlemen’s Beef Association, 1999. Conjugated Li-noleic Acid and Dietary Beef. An Update. Beef Facts: Nutrition, Series No. FS/N 016.

7. Ip, C., Scimeca, J.A., and Thompson, H.J., 1994. Conjugated linoleic acid. A powerful anticarcinogen from animal fat sources. Cancer, 74, 1050–1054.

8. Steinhart, Carol, 1996. Conjugated Linoleic Acid: The Good News about Animal Fat. Journal of Chemical Education, 73, A302.

http://jchemed.chem.wisc.edu/Journal/Issues/1996/Dec/ab-sA302.html

9. Campbell, T.C. and Junshi, C., 1994. Diet and chronic degenerative disease perspectives from China, American Journal of Clinical Nutrition, 59 (Suppl.), 11 535-11 615.

10. Bernstein, L. and Ross, R.K., 1993. Endogenous hormones and breast cancer risk. Epidemiol Reviews, IS, 48–65; Pike and others, 1993. Estrogens, progestogens, normal breast proliferation and breast cancer risk. Epidemiol reviews. 15, 17–35.

11. Prentice. R. and others, 1990. Dietary fat reduction and plasma oestrodial concentration in healthy postmenopausal women. J Natl Cancer Inst, 82, 129–134.

12. Waxman, Jonathan, 2001. The Prostate Cancer Book. London: Vermillion.

13. Campbell, T, Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Ben-bella Books.

14. Ornish, D and others, 2005. Intensive lifestyle changes may affect the progression of prostate cancer .Journal of Urology, 174 (3), 1065–1069.

15. Waxman, Jonathan, 2001. The Prostate Cancer Book. London: Vermillion.

16. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Ben-bella Books.

17. Plant, Jane and Tidey, Gill, 2005. Eating for Better Health. Virgin Books. See also, Campbell, T, Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Longterm Health. Benbella Books; Robbins, John, 1987. A Diet for a New America. Stillpoint Publishing.

18. Newby, J.A. and Howard, C.V, 2006. Environmental influences in cancer aetiology. Journal of Nutritional and Environmental Medicine, 2006, 1-59.

19. Campbell, T.C. and Junshi, C., 1994. Diet and chronic degenerative disease perspectives from China. American Journal of Clinical Nutrition, 59 (Suppl.), 11 535-31 615.

20. Food Chemical News, April 29, 1996.

21. Kurzer, M.S. and Xu, X., 1999. Dietary Phytoestrogens. Annual Reviews of Nutrition, 17, 353–381.

22. Adlercreutz, H„1995. Phyto-oestrogens: Epidemiology and a Possible Role in Cancer Protection. Environmental Health Perspectives,, 103 (Supppl 7), 103–112; Adlercreutz, H., Mazur, W, Bartels, P., Elomaa, У-V., Watanabe, S., Wahala, K., Landstrom, M., Lundin, E., Bergh, A., Damber, J.-E., Aman, P., Widmark, A., Johansson, A., Zhang, J.-X. and Hallmans, G., 2000. Phyto-oestrogens and Prostate Disease. J Nutr, 130, 658S-659S.

23. http://www.ifst.org/hottop34.htm

24. Adlercreutz, H., Mazur, W, Bartels, P., Elomaa, Y-V., Watanabe, S., Wahala, K., Landstrom, M., Lundin, E., Bergh, A., Damber, J.-E., Aman, P., Widmark, A., Johansson, A., Zhang, J.-X. and Hallmans, G., 2000. Phyto-oestrogens and Prostate Disease. J Nutr, 130, 658S-659S.

25. Zhou, J.-R., Gugger, E.T., Tanaka, Т., Guo, Y., Blackburn, G.L. and Clinton, S.K., 1999. Soy-bean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr, 129, 1628–1635; Davis, J.N., Singh, B., Bhuiyan, M. and Sarkar, EH., 1998, Genistein-in-duced upregulation of p21WAFl, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer, 32, 123–131; The Royal Society, 2000. Endocrine-disrupt-ing chemicals. Document 06/00. The Royal Society; Setchell, K.D.R., 1998. Phyto-oestrogens: the biochemistry, physiology and implications for human health of soy isoflavones, Nutrition, 68, 1333S-1346S.

26. Glenville, Marilyn, 2003. The New Natural Alternatives to HRT. Second edition. Kyle Cathie.

27. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Ben-bella Books.

28. Glenville, Marilen, 2003. The New Natural Alternatives to HRT. Second edition. Kyle Cathie.

29. Robbins, John, 1987. A Diet for a New America. Stillpoint Publishing; Kradjian, R.M., 1994. Save Yourself from Breast Cancer. New York: Berkley Books; McDougall, John, 2000. The McDougall Program for Women; Lee, John R., 1999. Natural Progesterone. Second revised edition. Jon Carpenter; Plant, Jane and Tidey; Gill, 2003. Understanding, preventing and overcoming osteoporosis. Virgin Books; Fox, Douglas, 2001. Hard cheese. New Scientist, 15 December 2001, 42–45.

30. http://wayne.unl.edu/00aprilcolumn.htm

31. Martin, Peter, 2002. Milk: Nectar or Poison? Sunday Times Magazine, July 21, 2002. 46–54.

32. Website of the American Cancer Society, http://www.cancer.org/docroot/eto/content/eto_5_3x_soy-bean.asp?siteare a=&viewmode=print

33. Gottlieb, Scott, 2003. Men should eat nine servings of fruit and vegetables a day. BMJ, 326, 1003.

34. UK Ministry of Agriculture, Fisheries and Food advice as reported in the Sunday Times, 1999.

35. Willet, WC., 1994. Micronutrients and cancer risk. Am J Clin Nutr, 59, (suppl), 1162S-5S. See also: Willett, Walter C., Colditz, Graham A. and Mueller, Nancy A., 1996. Strategies for Minimising Cancer Risk. Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 88–95.

36. Huang, M.-Т., Asawa Т., Ho C.-Т., Rosen R.T., eds, 1994. Food phytochemicals for cancer prevention I – fruits and vegetables. Washington, DC: American Chemical Society; Ho, C.-T., Osawa, Т., Huang, M.-T. and Rosen, R.T., eds, 1994. Food phytochemicals for cancer prevention II – teas, spices, herbs. Washington, DC: American Chemical Society; American Institute for Cancer Research, ed., 1996. Dietary phytochemicals in cancer prevention and treatment. New York: Plenum Press; Liu, R.H. and Espinosa, A., 2000. Bio-active Compounds from Fruits and Vegetables in the Prevention of Cancer. In: Agriculture in the New Century: Managing Bio-Resources and Bio-Diversity, National Taiwan University, Taipei, Taiwan, 53–59.

37. Greenwald, Peter, 2002. Cancer chemoprevention. BMJ, 324, 714–718.

38. Alpha-Tocopherol Beta-Carotene Cancer Prevention Study Group, Heinonen, O.P., Huttunen, J.K. and Albanes, D., 1994. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Mod,

330, 1029–1035; Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R. and Class, A., 1996. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med, 334, 1150–1355.

39. Ursell, Amanda, 2007. Eat a rainbow to stay healthy. The Times (T2), 6 February, 2007.

40. Gunnell, D L and 10 others, 2003. Are diet – prostate-cancer association mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. British Journal of Cancer, 88; 1682–1686.

41. Mucci, L.A. and six others, 2001. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system. BJU Int. 87, 814–820.

42. http://www.flax.com.fda

43. http://info.cancerresearchuk.org/healthyliving/dietandhealth-yeating/ theepicstudy

44. Am J Epidemiol, 1994. 139 (11), s37.

45. Inside Story. Which? April 2002, 4.

46. Lu, C. and others, 2006. Organic diets significantly lower children’s dietary exposure to organophosphorus pesticides. Environmental Health Perspectives, 114 (2), 260–263.

47. Doll, R. and Peto, R., 1981. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. New York: Oxford University Press.

48. Boseley, Sarah, 2006. Expert revered for painstaking work that proved link between smoking and cancer. Guardian, 8 December, 2006.

49. Colborn, T.T., 1993. Developmental effects of endocrine-dis-rupting chemicals in wildlife and humans. Environmental Health Perspectives, 101 (5), 378–384.

50. McKinlay, R. and others, in press. Endocrine-disrupting pesticides: implications for risk assessment.

51. Royal Commission on Environmental Pollution, 2005. Special report, crop spraying and health of residents and bystanders.

52. Mittelstaedt, Martin, 2002. Data point to breast-cancer risk. Globe and Mail, 22 November 2002, A5.

53. McMichael, A.J., 1993. Planetary Overload– Global Environmental Change and the Health of the Species. Cambridge University Press.

54. Royal Commission on Environmental Pollution, 2002. A Short Report on the Environmental Effects of Civil Aircraft in Flight. Royal Commission on Environmental Pollution.

55. Bristow, Amanda, 2002. Which? April 2002, 22–23.

56. Campbell, T Colin, Campbell, Thomas M. II, 2006. The China Study. Benbella Books; McDougall, J. and others, 1995. Rapid reduction of serum cholesterol and blood pressure by a twelve-day, very low fat, strictly vegetarian diet. J Am Coll Nutr, 14, 491–496.

57. ICON. September 2002.

58. http://www.eurocbc.org/page641.html http://www.ciwf.co.uk/Trust/FF/farm_facts_fish_farming. htm

59. Cho, E. and others, 2006. Red meat intake and risk of breast cancer among premenopausal women. Archives of International Medicine, 166, 2253–2259.

60. http://info.cancerresearchuk.org/healthyliving/dietandhealth-yeating / theepicstudy

61. JAMA, 1985, 254 (3), 356–357.

62. http://www.prostatepointers.org/cmyers/pf0696.html

63. http://info.cancerresearchuk.org/healthyliving/dietand-healthycating/ theepicstudy

64. J Nat Cancer Inst, 1994, 86 (18), 1409–1415.

65. AmJ Epidem, 1994, 139 (11), S37.

66. http://www.prostatepointers.org/cmyers/pf0696.html; American Heart Association Cookbook, fifth edition, 1995. New York: Times Books, Random House; Pritikin, Nathan, 1979. The Pritikin Program for Diet and Exercise. New York: Bantam Books; Ornish, D., 1990. Dr Dean Ornish's Program for Reversing Heart Disease. New York: Ballantyne Books.

67. Van de Weyer, Courtney, 2005. Changing diets, changing minds. Sustain.

68. www.annieappleseedproject.org/nutgenprotin.html

69. Van de Wever, Courtnev, 2005. Changing diets, changing minds. Sustain.

70. Trichopoulos, Dimitrios, Li, Frederick E and Hunter, David J., 1996. What Causes Cancer? Scientific American, Special Issue, What you need to know about Cancer, September, 275, 3, 80–85.

71. Djamgoz, M.B.A. and Isbilen, B., 2006. Dietary compounds as anti-cancer agents: a preliminary evaluation of ion channels and membrane excitability as possible target mechanisms. The Lancet.

72. http://www.findarticles.com/cf_0/m0FKA/5_62/62702338/ p 1/article, jhtmi? term = turmeric%2C + Liz + Brown

73. Steinmetz, K.A. and Potter, J.D., 1991. Vegetables, fruity and cancer, II. Mechanisms. Cancer Causes Control, 1, 427–442; Lam, L.K.T., Zhang, J., Hasegawa, S. and others, 1994. Inhibition of chemically induced carcinogenesis by citrus liminoids. In: Huang, M-Т., Asawa, Т., Ho, C-T. and Rosen, R.T., eds. Food phytochemicals for cancer prevention, I – fruits and vegetables. Washington, DC: American Chemical Society, pp, 209–219; Zheng, C.Q., Zhang, J., Kenney, P.M. and Lam, L.K.T., 1994 Stimulation of glutathione S-transfcrase and inhibition of carcinogenesis in mice by celery seed oil constituents. In: Huang, M.-Т., Asawa, Т., Ho, C.-T. and Rosen, R.T., eds, Food phytochemicals for cancer prevention. I – fruits and vegetables. Washington, DC: American Chemical Society, pp. 230–238.

74. Nakatani, N, 1994. Chemistrv of antioxidants from Labiatae herbs. In: Ho, C.-Т., Osawa, Т., Huang, M.-T. and Rosen, R.T., eds. Food phytochemicals for cancer prevention, II– teas, spices, herbs. Washington, DC: American Chemical Society, pp. 144–153.

75. Ho, C.-Т., Ferraro, Т., Chen, Q and others; 1994. Phytochemicals in teas and rosemary and their cancer-preventive properties. In: Ho, C.-Т., Osawa, Т., Huang, M.-T. and Rosen, R.T., eds. Food phytochemicals for cancer prevention, II– teas, spices, herbs. Washington, DC: American Chemical Society, pp. 2-19.

76. Kikuzaki, H. and Nakatani, N, 1993. Antioxidant effects of some ginger constituents. Journal of Food Science, 58, 1407–1410.

77. Zheng, G.Q., Kenney, P.M. and Lam, L.K.T., 1993. Potential anticarcinogenic natural products isolated from lemongrass oil and galanga root oil. Journal of Agricultural and Food Chemistry, 41, 153–156; Zheng, G.Q., Kenney, P.M. and Lam, L.K.T.,

1992. Anethofuran, carvone, and limonene: potential cancer chemopreventive agents from dill weed oil and caraway oil. Planta Medico, 58, 338–341; Zheng, G.Q., Kenney, P.M., Zhang, J. and others, 1993. Chemoprevention of benzo[a]pyrene-in-duced forestomach cancer in mice by natural phthalides from celery seed oil. Nutr Cancer, 19, 77–86; Zheng, G.Q., Kenney, P.M. and Lam, L.K.T., 1992. Sesquiterpenes from clove (Eugenia caryophyllata) as potential anticarcinogenic agent s. Journal of Natural Products, 55, 999-1003; Zheng, C.Q, Kenney, P.M. And Lam, L.K.T., 1992. Myristicin: a potential cancer cherno-preventive agent from parsley leaf oil. J Agric Food Chem, 40, 107–110.

78. http://www.pcrm.org/health/Dairy_and_Prostate_Cancer/d-p-article.html;

World Cancer Research Fund and American Institute for Cancer Research. 1997. Food, Nutrition and the Prevention of Cancer: a global perspective. Washington DC: American Institute for Cancer Research, (http://www.aicr.org/report2.htm)

79. Journal of the American Diabetic Association, May 2001; http://www.wad-sworth.corn/nutrition_d/special_features/news/nutu1201.html.

80. Thompson, L.U., 1994. Antioxidants and hormone-mediated health benefits of whole grains. Critical Reviews in Food Science and Nutrition, 34, 473–497.

81. Thompson, L.U., 1992. Potential health benefits of whole grains and their components. Contemp Nutr, 17 (6), 1–2.

82. Elson, C.E. and Yu, S.G., 1994. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables./ Nutr, 124, 607–614.

83. Elson, C.E. and Yu, S.G., 1994. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables./ Nutr, 124, 607–614.

84. Fox, Douglas, 2002. Bread to blame for plague of pimples. New Scientist, 7, December 2002.

85. http://www.dorway.com/badnews.html

86. http://www.stevia.net; http://www.holisticmed.com/sweet/

87. Pesticide residues found in Indian bottled water. 2003. BMJ, 326, 352.

88. http://www.annieappleseedproject.org/nutgenprotin.html, reporting on a conference on nutritional genomics and proteo-mics in cancer prevention in September 2002, at the USNIH, Bethesda.

89. Why tea is not so good for you after all. The Times, 9 January 2007.

90. www.diagnose-me.com

91. http://rescarch.kib.ki.se/e-uven/public/51419.html

92. ENDS Report.

93. http://www.vegansociety.com/html/info/info28.html

94. http://www.vegansociety.com

95. Royal College of Physicians, 2002. Nutrition and patients: a doctor’s responsibility,

96. http://www.pcrm.org/health/Dairy_and_Prostate_Cancer/ d_p_article.html

97. www.mdanderson.org/departments/nutririon/display.cfm/ id=5 If759d8-98b2-lld5”813300508b603al4&method = display full&pn = 51f7589e-98b2-lld5-813300508b603al4

Дополнение к главе 6

1. Berger, Abi, 2002. Science commentary: What does zinc do? BMJ, 325, 1062–1063.

2. Hambridge, K. M., Casey, C. E. and Krebs, N. E, 1986. Zinc, In: Trace Elements in Human and Animal Nutrition, Fifth Edition, Mertz, W, Ed. Academic Press, Inc. London.

3. Medical Report: Prostate Cancer. ICON, 2002, 1 (5), 8-10.

4. McCusker. R.H., 1998. Controlling Insulin-Like Growth Factor Activity and the Modulation of Insulin-Like Growth Factor Binding Protein and Receptor Binding. J Dairy Sei., 81, 1790–1800.

5. Josefson, Deborah, 2002. Popping a multivitamin daily can keep disease at bay. BMJ, 324, 1544.

6. Van de Weyer, C., 2005. Changing diets, changing minds. Sustain.

7. Van de Weyer, C., 2005. Changing diets, changing minds. Sustain.

8. The Lancet, 1976, 880–881.

9. Johnson, C., 1999, Environmental controls in iodine deficiency disorders (IDD), Earthworks, 9 November, p. 3, British Geological Survey.

10. Greenwald, Peter, 1996. Chemoprevention of cancer. Scientific American, September 1996, 96–99.

11. Olivotto, Ivo, Hotter, Abram and Lesperance, Mary, 2002. In Breast Cancer Research and Treatment, http://www.nlm.nih. gov/ medlineplus/news/fullstory_l 0706.html

12. Bender, David A., 2002. Dally doses of multivitamin tablets. BMJ, 325, 173–174.

13. Annals of Internal Medicine, July 1, 2003; http://www.nlm.nih. gov/ medlineplus/news/fulls tory_l 3210.html

14. Kmietowicz, Zosia, 2003. Food watchdog warns against high doses of vitamins and minerals. BMJ, 326, 1001.

15. http://www. nlm.nih.gov/medlineplus/news/fullstory_13219. html

16. Gluud, C., 2007. Journal of the American Medical Association, 297, 842; see also Can vitamin supplements do more harm than good? New Scientist, v28, February 2007, 6.

17. Oakley, Godfrey P., 2002. Delaying folic acid fortification of flour. BMJ, 324, 1348–1349.

18. Reynolds, Edward, 2002. Fortification of flour with folic acid. BMJ, 324,918.

19. Feldman, David, 2002. Pathways of Vitamin D Action to Inhibit Prostate Cancer Cell Growth, www.annieappleseedproj-ect.org/nutgenprotin.html

20. Campbell, T.C, and Campbell, T.M., 2006. The China Study. Benbella Books.

21. http://bioscience.igh.cnrs.fr/2001/v6/d/hansen/2.asp

22. Seol, J.G. and five others, 1998. Telomerase activity in acme myelogenous leukemia: clinical and biological implications. Br J Haematology, 100, 156–165; Savoysky, E. and seven others, 1996, Down-regulation of telomerase activity is an early event in the differentiation in HL-60 cells. Biochem Biophys Res Commun, 226, 329–334; Albanell, J. and five others, 1996. Tel-omerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Cancer Res, 56, 1503–1508.

23. Campbell. T. Colin, Campbell, Thomas М. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health, Ben-bella Books.

24. Barretto, A.M., Schwartz, G.G., Woofruff, R. and Cramer, S.C., 2000. 5-hydroxyvitamin D-3, the prohormone of 1,25-dihydroxyvitamin D-3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiology Biomarkers ^Prevention, 9, 3, 265–270.

25. http://www.rense.com/gencral/dair.htm

26. Spallholz, J.E., Stewart, J.R., 1989. Advances in the role of minerals in immunobiology. Center for Food and Nutrition, Texas Tech University, Lubbock 79409. Biol Trace Elem Res Mar, 19 (3) 129–151.

27. Gynecologic, 2004, 93, 320–327.

28. Redbook, April, 1989, vl72, n6, p. 96 (5).

29. Niki, E., Noguchi, N, Tsuchihashi, H. and others, 1995. Interaction among vitamin C, vitamin E and beta-carotene. Am J Clin Nutr, 62 (Suppl), 1322S-1326S.

30. Craig, Winston J., 2002. Phyiochemicals: Guardians of Our Health,

http://www.andrews.edu/NUFS/phyto.html, 03/12/02.

31. New Scientist, August 2006.

32. Anon. 2003. Growing problems: Endocrine disruptors under the spotlight. ENDS Report, 336, 20–23.

33. Vikse, R. and others, 1999. Heterocyclic amines in cooked meat. Tidsskr Nor Laegeforen, 119 (1), 45–49.

34. Skog, K. and others, 1997. Polar and non-polar heterocyclic amines in cooked fish and meat products and their corresponding pan residues. Food Chemical Toxicology, 35 (6), 555–565.

35. BMJ, 325, 1250.

36. JAMA, 1985, 254 (3), 356–357.

37. ЛFSTAN/NCFST Acrylamide in Food Workshop, 1989. White paper for Working Group 5: Risk Communication. National Research Council, National Academy of Sciences (NRC-NAS). Improving Risk Communication. National Academy Press. Washington DC.

38. Fleck, Fiona, 2002. Experts launch action on staple foods. BMJ, 325, 120; Anon. 2002. Acrylamide dues found in Asparagine. ICON, 1 (6), 24.

39. US Environmental Protection Agency, http://www.epa.gov/ ttn/atw/hlthef/acrylami.html

40. http://ntp-server.niehs.nih.gov/htdocs/Chem_H6cS/NTP_ Chem7/Radian79-06-l.html

41. http://www.nsc.org/library/chemical/Acrylami.htm

42. Anon. 1997. Acrylamide. Toxic Air Contaminant Identification. List Summaries – ARB/SSD/SES. September 1997.

43. Advisory Committee on Hazardous Substances. Sixth Annual Report (2001–2002). Department for Environment, Food and Rural Affairs; The Royal Commission on Environmental Pollution, 2003. Chemicals in products: safeguarding the environment and human health. Report 24.

44. US Environmental Protection Agency, http://www.epa.gov/ ttn/atw/hlthef/acrylami.html

45. http://ntp-server.niehs.nih.gov/htdocs/Chem_H6cS/NTP_ Chemy/Radian79-06-l.html

46. http://www.foodstandards.gov.uk/mi3ltimedia/webpage/ acrylamide_study_faq

47. www.cancerresearchuk.org

48. White, Craig A. and Macleod, Una, 2002. ABC of psychological medicine: Cancer. BMJ, 325, 377–380.

49. Walsh, Kiri, King, Michael, Jones, Louise, Tookman, Adrian and Blizzard, Robert, 2002. Spiritual beliefs may affect outcome of bereavement: prospective study. BMJ, 324, 1551–1554.

50. White, Craig A. and Macleod, Una, 2002. ABC of psychological medicine: Cancer. BMJ, 325, 377–380.

51. White, Craig A. and Macleod, Una, 2002. ABC of psychological medicine: Cancer. BMJ, 325, 377–380.

52. White, Craig A. and Macleod, Una, 2002. ABC of psychological medicine: Cancer. BMJ, 325, 377–380.

53. Petticrew, Mark, Bell, Ruth and Hunter, Duncan, 2002. Influence of psychological coping on survival and recurrence in people with cancer: systematic review. BMJ, 325, 1066–1069.

54. Graham, J, Ramirez, A, Love, S, Richards, M and Burgess, C.

2002. Stressful life experiences and risk of relapse of breast cancer: observational cohort study. BMJ, 324, 1420–1422.

55. Beales, D., 2004. Beyond mind-body dualism: implications for patient car t. Journal of Holistic Healthcare, 1 (3).

56. Ernst, Edzard (ed.), 2001. The desktop guide to complementary and alternative medicine. Mosby.

57. King, Michael and five others, 2002. Effectiveness of teaching general practitioners skills in brief cognitive behaviour therapy to treat patients with depression: randomised controlled trial. BMJ, 324, 947.

58. http://www.nccn.org/patient_gls/_english/_prostate/

59. European Journal of Cancer, 2003, 39, 1562–1567; quoted in BMJ, 327, 402.

60. Plant, Jane and Stephenson, Janet, in preparation. Breakthrough Anxiety and Depression.

61. Bartram, Thomas, 1998. Bartram’s Encyclopedia of Herbal Medicine. London: Robinson.

62. Miller, G H, 1996. Can Active or Passive Smoking Increase Breast Cancer Mortality? Cancer Detect Prevent 20 (5).

63. Mayor, Susan. 2002. Pregnancy and early smoking increases breast cancer risk. BMJ, 325, 12 October 2002, 793.

64. Cancer Epidemiology, Biomarkers and Prevention, July 2003; http://www.nlm.nih.gov/medlineplus/news/fullstory_13352. html

65. Plant, Jane and Tidey, Gill, 2003. Understanding, preventing and overcoming osteoporosis. Virgin Books.

66. Goodman-Gruen, D. and Barrett-Connor, E., 1997. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. American Journal of Epidemiology, 145, 970–976; Kaklamani, VG., Linos, A., Kaklamani E., Markaki, I. and Mantzoros, C., 1999. Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. Journal of Clinical Oncology, 17. 813–817.

67. Colborn, Т., Dumanoski, D. and Myers, J.P., 1996. Our Stolen Futures, Dutton, Penguin Books, USA.

68. The Environment Agency, March 2000. Endocrine-disrupting substances in the environment: The Environment Agency's Strategy, The Environment Agency, Bristol, UK.

69. Miller, WR. and Sharpe, R.M., 1998. Environmental oestro-gens and human reproductive cancers. Endocrine-Related Cancer, S, 69–96; Plant, J.A. and Davis, D.L., 2003. Breast and prostate cancer: sources and pathways of endocrine-disrupting chemicals (EDCs). In Geology and Health. Skinner, H.C.W and Berger, A.R. (editors). OUP. 95–99.

70. McKinlay, R. and others, in press. Endocrine disrupting pesticides: implications for risk assessment.

71. Toppari, J., Larsen, J.C., Christiansen, P., Giwercman, A., Grandjean, P., Guillette, L-J., Jr, Jegou, B., Jensen, Т.К., Jouan-net, P., Keiding, N., Leffers, H., McLachlan, J.A., Meyer, O., Muller, J., Rajpert-De Meyts, E., Scheike, Т., Sharpe, R.M., Sumpter, J.S., and Skakkebaek, N.E., 1996. Male reproductive health and environmental xenoestrogens. Environmental Health Perspectives, 104, 741–803.

72. www.cancersupportinternational.com

73. The Royal Commission on Environmental Pollution, 2003. Chemicals in products: safeguarding the environment and human health. Report 24; Annual Reports of the (UK) Chemical Stakeholders Forum, 2002, and The Advisory Committee on Hazardous Substances, 2002; Miller, WR. And Sharpe, P.M., 1998. Environmental oestrogens and human reproductive cancers. Endocrine-Related Cancer, 5, 69–96.

74. Charlier, C.C.J., 2002. Determination of organochlorine pesticide residues in the blood of healthy individuals. Clinical Chemistry and Laboratory Medicine, 44, 361–364; WWF, 2003. UK national biomonitoring survey. WWF.

75. MDuffie, H.H., 2005. Host factors and genetic susceptibility: a paradigm of the conundrum of pesticide exposure and cancer associations. Reviews on Environmental Health. 20 (2), 77-101.

76. Mathur, V, 2002. Breast cancer incidence and exposure to pesticides among women originating from Jaipur. Environment International, 28 (5), 331–336; Starek, A., 2003. Estrogen and organochlorine xenoestrogens and breast cancer risk. International Journal of Occupational Medicine and Environmental Health. 16 (2), 113–124.

77. Frigo, D.E., 2004. Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 МАРК pathway. Carcinogenesis, 25 (Feb), 249–261; Lewis, J.S. and others, 2005. Differential effects of 16-hydroxyestrone and 2-meth-oxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. Journal of Molecular Endocrinology, 34, 91-105; Tessier, D.D., 2001. Increased ErbB-2 tyrosine kinase activity, МАРК phosporylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides. Toxicological Sciences. 60 (1), 38–43.

78. Swan S.H. and others, 2005. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environmental Health Perspectives, 113, (8).

79. Kawauchi, H., 2002. Identification of growth hormone in the sea lamprey, an extant representative of a group of the most ancient vertebrates. Endocrinology, 143 (12), 4916–4921; Park, J.I., 2005. Conservation of the heterodimeric glycoprotein hormone subunit family proteins and the LGR signalling system from nematodes to humans. Endocrine Journal, 26 (3), 267–276.

80. Environmental Endocrine Disruptors: A Handbook of Property Data, John Wiley and Sons.

81. Edwards, T.T., 2006. Reproductive dysgenesis in wildlife: a comparative view. International Journal of Andrology, 29 (1), 109–121; Guillette, L.L., 1999. Plasma steroid concentrations and male phallus size in juvenile alligators from seven Florida lakes. General and Comparative Endocrinology, 116(3), 356–372.

82. Colborn, Т., Dumanoski, D. and Myers, J.P., 1996. Our Stolen Futures, Dutton, Penguin Books, USA.

83. Webb, S.F., 2000. Risk assessment approaches for Pharmaceuticals. In: International Seminar: Pharmaceuticals in the Environment, Technological Institute, Section on Environmental Technology, Brussels, 2000.

84. Kolpin, D.A., Furlong, E.T., Meyer, M.T., Thurman, E.M., Zaugg, S.D., Barber, L.B. and Buxton, H.T.; 2002. Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in US Streams, 1999–2000: A National Reconnaissance. Environmental Science & Technology, 36, 1202–1211.

85. McQuillan, D., Mullany, J., Parker, J., Mills, D., Sherrell, K. and Chapman, Т.Н., 2000. Drug Residues in Ambient Water: Initial Surveillance in New Mexico, USA. December 2000 Progress Report, http://www.nmenv.state.nm.us/gwb/drugs. html; Morelli, J., 2000. Are Our Medicines Tainting the Environment?

http://webmd.lycos.com/content/article/25/1728_58159?

86. McQuillan, D., Mullany, J., Parker, J., Mills, D., Sherrell, K. and Chapman, Т.Н., 2000. Drug Residues in Ambient Water: Initial Surveillance in New Mexico, USA. December 2000 Progress Report, http://www.nmenv.state.nm.us/gwb/drugs. html

87. The Royal Commission on Environmental Pollution, 2003. Chemicals in products: safeguarding the environment and human health. Report 24.

88. Hamburger Umwelt Institute, 1997. Poor Design Practices – gaseous emissions form complex products.

89. Brown, S.K. and Cheng, M., 2000. Volatile Organic Compounds (VOCs) in New Car Interiors. Presented at the 35th International Clean Air & Environment Conference Sydney, 26–30 November 2000.

90. http://www.le.ac.uk/ieh

91. Clapp, R.W and others, 2005. Environmental and occupational causes of cancer. The Lowell Centre for Sustainable Production, University of Massachusetts Lowell.

92. The Globe and Mail, November 22, 2002, page A5. Data point to breast-cancer risk. By Martin Mittelstaedt.

93. Newby, JA. and Howard, C.V, 2006. Environmental influences in cancer aetiology. Journal of Nutritional and Environmental Medicine; 2006, 1-59.

94. Clapp, R.W and others, 2005. Environmental and occupational causes of cancer. The Lowell Centre for Sustainable Production, University of Massachusetts Lowell.

95. Birnbaum, L.S. and Fenton, S.E., 2003. Cancer and developmental exposure to endocrine disruptors. Environmental Health Perspectives, 11 (4), 389–395.

96. www.obgyn.nct/newsrx/womens_health-Colorectal_Cancer-20001214-7.asp

97. http://info.cancerresearchuk.org/healthyliving/dietand-healthycating/ theepicstudy

98. www.ucdmc.ucdavis.edu/ucdhs/health/a-z/06BreastCancer/ doc06lowerisk.html

99. Epidem. 1994, 23 (6), 1133–1136.

100. Spurgeon, D., 2006. Vitamin D is associated with a lower risk of cancer. BMJ, 332, 70.

101. Miller, WR. and Sharpe, R.M., 1998. Environmental oestro-gens and human reproductive cancers. Endocrine-Related Cancer, 5, 69–96.

102. http://cis.nci.nih.gov/fact/3_13.htm

103. Gottlieb, Scott. 2002. Study supports evidence on oral contraception and breast cancer. BMJ, 325, 6 July 2002, 8.

104. Writing Group for the Women’s Health Initiative Investigators. 2002. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Journal of the American Medical Association, 288, № 3.

105. Collaborative Group on Hormonal Factors in Breast Cancer,

1997. Breast cancer and hormone replacement therapy. Lancet,ЪЬЪ, 1047–1059.

106. Schairer, C., Lubin, J., Troisi, R., and others, 2000. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA, 283(4), 485–491.

107. www.nih.gov/news/pr/nov2002/nichd-29.htm

108. Ross, R.K., Paganini-Hill, A., Wan, P.C. and others, 2000. Effective hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst,

92, 328–332. Schairer, C., Lubin, J., Troisi, R. and others. 2000.

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA, 283 (4), 485–491.

109. The Times. 15 December 2006.

110. Ernst, E (editor), 2001. The Desktop Guide to Complementary and Alternative Medicine: an evidence based approach. Mosby.

111. Lee, John R, 1999. Natural Progesterone. Second revised edition. Jon Carpenter.

112. Cowan, L.D., Gordis, L., Tonascia, J.A. and Jones, G.S., 1981. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiology, 114, 209–217.

113. Hrushesky, WJ.M., 1996. Breast cancer, timing of surgery, and the menstrual cycle: call for prospective trial. / Womens Health, 5, 555–566.

114. Mohr, P.E., Wang, D.Y., Gregory, WM., Richards, M.A. and Fentiman, I.S., 1996. Serum progesterone and prognosis in operable breast cancer. British J Cancer, 73, 1552–1555.

115. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

116. Dibble, S.L. and others, 2002. Risk factors for ovarian cancer; lesbian and heterosexual women. Oncol Nursing Forum, 29 (1)? El-7.

117. Ives, A. and Semmens, J., 2007. Pregnancy after breast cancer: population based study. BMJ, 334, 194.

118. www.cancer.org/docroot/cri/content/cri_2_4_5x_what_hap-pens_after_treatment_5.asp?sitearea=cr

119. http://www.cancer.org/docroot/cri/content/cri_2_6x_can_ha-ving_an_abortion_cause_or_contribute_to_breast_cancer.asp

120. http://www. cancer.org/docroot/cri/content/cri_2_6x_can_ having_an_abortion_cause_or_contribute_to_breast_cancer.asp

121. www.cspinet.org/new/200206251.html

Дополнение к главе 7

1. Campbell, Т., Colin, Campbell, Thomas М. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health, Ben-bella Books.

2. Kannel Ж.В. and others, 1961. Factors of risk in the development of coronary heart disease – six year follow up experience. Anna Internal medi., SS.

3. Campbell, T. Colin, Campbell, Thomas М. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet 3 Weight Loss and Long-term Health , Benbella Books.

4. Campbell, T.C. and Junshi, C., 1994. Diet and chronic degenerative disease perspectives from China. American Journal of Clinical Nutrition, 59 (Suppl.), 11 535-11 615.

5. Marwick, Charles, 2003. Food industry obfuscates healthy eating message, BMJ, 327, 121.

6. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006, The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet 3 Weight Loss and Long-term Health , Benbella Books.

7. Schlosser, Eric, 2002. Fast Food Nation. Penguin Books.

8. Martin, Peter, 2002. Milk: Nectar or Poison? Sunday Times Magazine, 21 July 2002, 46–54.

9. Mercer, Chris, 2007. EU unveils milk shake-up plans, www. foodnavigator.com

10. http://www.cafod.org.uk

11. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

12. Anon, 2003. UK supports exclusive breast feeding for six months. BMJ, 326, 1052.

13. Laurens, Claire, 2003. Baby milk company fined for advertising direct to consumers. BMJ, 327, 307.

14. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

15. Atkins, P.J., 2005. Fattening children or fattening farmers? School milk in Britain, 1921–1941. Economic H-58.

16. http://www.nationaldairycouncil.org

17. Kradjian, R.M., 1994. Save Yourself from Breast Cancer. Berkley Books, New York.

18. Martin, Peter, 2002. Milk: Nectar or Poison? Sunday Times Magazine. 21 July 2002, 46–54.

19. Outwater, J.L. and others, 1997. Dairy Products and Breast Cancer: the IGF-1, estrogen and bGH hypothesis. Mod Hypotheses. 48, 453–461.

20. European Commission, Scientific Committee on Veterinary Measures relating to Public Health. 1999. Report on Public Health Aspects of the Use of Bovine Somatotropin, 15–16 March.

21. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer inst, 92, 1472–1489.

22. http://www.milksucks.com/osteo.html

23. New, S.A. and Francis, R.M., 2003. Science in Parliament, 60 (4)’21‘

24. Plant, Jane and Tidey, Gill, 2004. Science in Parliament. 61 (1), 28.

25. Kradjian, R.M., 1994. .Save Yourself from Breast Cancer. Berkley Books, New York.

26. New, S.A. and Francis, R.M., 2004. Science in Parliament, 61 (3)? 21.

27. Robbins, John, 1987. A Diet for a New America. Stillpoint.

28. www.foodnavigator.com

29. Parry, Vivienne, 2007. It’s udder confusion. The Times (Body and Soul). 20 January 2007.

30. Butler, Justine, 2007. Second opinion. The Times (Body and Soul), 27 January 2007.

31. ICON, 2006, issue 4.

32. Bristow, A., 2002. Organic processed food. Which? April 2002, 22–23.

33. Martin, Peter, 2002. Milk: Nectar or Poison? Sunday Times Magazine, 21 July 2002. 46–54.

34. Bristow, A., 2002. Organic processed food. Which? April 2002, 22–23.

35. Inside Story. Which? April 2002, 4.

36. Clapp, R.W, Howe, K.H, and Jacobs, M.M., 2005. Environmental and occupational causes of cancer, www.sustainable-production.org

37. Plant, J.A., Turner, K.T., and Highley, D.E., 1998. Minerals and the environment. Proceedings of Minerals c98 Conference, June 1998: Republished in the Mineralogical Society Bulletin, No. 119, July 1998, 3-11; Mineral Planning 77, December 1998, 3–8; IM&M Journal, December 1998, 1, 12, 331–336.

38. Kushi L.H. and others, 2007. Lifestyle factors and survival in women with breast cancer. The Journal of Nutrition, Special supplement; Intern. Research conf. on food, nutrition and cancer, 236S-242S.

39. Getz, Linn, Sigurdsson, Johann A. and Hetlevik, Irene, 2003. Is opportunistic disease prevention in the consultation ethically justifiable? BMJ, 327, 498.

40. Research muddled by political pressures. The Times (Public Agenda), 19 August 2003.

41. Chaturvedi, P., 2003. Medical community may be partly responsible for cancer misery. BMJ, 326, 1146.

42. Kmietowicz, Zosia, 2002. Research spending on cancers doesn’t match their death rates. BMJ, 325, 920.

43. Smith, Richard, 2003. Do patients need to read research? BMJ, 326, 3307.

44. Smith, Richard, 2003. Do patients need to read research? BMJ, 326, 1307.

45. Corrie, Pippa, Shaw, Justin and Harris, Roy, 2003. Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study. BMJ, 327, 320–321.

46. Wald, Nicholas J. and Morris, Joan K… 2003. Teleoanalysis: combining data from different types of study. BMJ, 327, 616–618.

47. The Times (Public Agenda), 6 March 2007.

48. Smith, Richard, 2003. Editor’s choice: The screening industry. BMJ, 326,26 April 2003.

49. Lechin, Fuard and others, 2002. N euro circuitry and Neuroauto-nomic Disorders. Karger.

50. Gottlieb, Scott, 2003. US drug sales continue to rise. BMJ, 326, 518.

51. Gottlieb, Scott, 2002. Drug companies maintain ‘astounding’ profits, BMJ, 324, 1054.

52. Kjaergard, Lise L. and Als-Nielsen, Bodily 2002. Association between competing interests and authors’ conclusions: epide-miological study of randomised clinical trials published in the BMJ. BMJ, 325, 249–252.

53. Eaton, Lynn, 2003. Readers want transparency in link between doctors an drug firms. BMJ, 326, 1352.

54. Mayor, Susan, 2002. Researchers claim clinical trials are reported with misleading statistics. BMJ, 324, 1353.

55. JAMA, 2003, 389, 454–465, quoted by Hopkins Tanne, Janice, 2003. Industry is deeply involved in funding US research. BMJ, 326, 179.

56. Tonks, Alison, 2002. Authors of guidelines have strong links with drugs industry. BMJ, 324, 383.

57. Spurgeon, David, 2002. Doctors accept $50 a time to listen to drug representatives. BMJ, 324, 1113.

58. Gottlieb, Scott, 2003. A fifth of Americans contact their doctor as a result of direct to consumer drug advertising. BMJ, 325, 854.

59. BMJ, 2003. Drug companies want to inform patients. BMJ, 326, 1286.

60. Watson, Rory, 2003. EU health ministers reject proposal for limited direct to consumer advertising. BMJ, 326, 1284.

61. Watson, R., 2006. Cancer group denies company funding will influence its agenda. BMJ, 333, 874.

62. Mayor, Susan, 2002. GMC issues new guidance on clinical research. BMJ, 324,384.

63. Marwick, Charles, 2002. US tackles drug company gifts to doctors. BMJ, 325, 795.

64. Mosconi, Paola, 2003. Declaration of competing interests is rare in Italian breast cancer associations. BMJ, 327, 344.

65. Herxheimer, A., 2003. Relationships between the pharmaceutical industry and patients’ organisations. BMJ, 326, 1208–1210.

66. Hirst, J., 2003. Charities and patient groups should declare interests. BMJ, 326, 1211.

67. Clark, Jocalyn, 2003. A hot flush for Big Pharma. BMJ, 327, 400.

68. Writing Group for the Women’s Health Initiative Investigators, 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288, 321–333.

69. The Times, 15 December 2006.

70. Moynihan, Ray, 2003. US seniors group attacks pharmaceutical industry ‘fronts’. BMJ, 326, 351.

71. Cho, E, and others, 2006. Red meat intake and risk of breast cancer among premenopausal women. Archives of International Medicine, 166, 2253–2259.

72. Lenzer, Jeanne, 2002. The operation was a success (but the patient died). BMJ, 325, 664.

73. Moynihan, Ray, 2003. Blurring the boundaries. BMJ. 326, 1094.

74. The selling of a wonder drug. The Guardian, 29 March 2006.

75. http://en.wikipedia.org/wiki/Trastuzumab.

76. Barrett, A. and others, 2006. How much will Herceptin really cost? BMJ, 333, 118–120.

77. Bartlett, Christopher, Sterne, Jonathan and Egger, Matthias, 2002. What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers. BMJ, 325,

81.

78. http://www.madnessmansion.com/!!jimkc/txt/ambulanc.txt/ http://www.public.asu.edu/!! tadams2/Quotes/Ambulance

79. www.cancersupportinternational.com

80. Campbell, T, Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Ben-bella Books.

81. Robbins, John, 1987. A Diet for a New America. Stillpoint.

82. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

Литература

Blauer, Stephen, 1989. The Juicing Book, New York, Avery Publishing Group, 176 p.

Bremness, Lesley, 1990. World of Herbs, London, Ebury Press, 176 p.

Conil, Christopher and Jean, 1993. New Tofu Recipes, W Foulsham and Co Ltd, USA.

Lamont, Heather, 1988. The Gourmet Vegan, London, Victor Gollanez, 160 p.

Jaffrey, Madhur, 1981. Eastern Vegetarian Cooking, London, Arrow Books, 544 p.

Pert, CB, 1997. Molecules of Emotion: Why you Feel the Way you Feel, London, Simon & Schuster.

Ramsay, Ray, 1994. Easy Thai Cooking, Wellingborough, J В Fairfax Press, 80 p.

Shurtleff, William and Aoyagi, Akiko, 1975. The Book of Tofu: Food for Mankind, Autumn Press, USA.

So Yan-Kit, 1992. Classic Food of China, London, Macmillan, 400 p.

Thorson Editorial Board, 1989, The Complete Raw Juice Therapy, London, Thorsons, HarperCollins, 128 p.

Wheater, Caroline, 1993. Juicing for Health, London, Thorsons, HarperCollins, 256 p.

Рекомендуемая литература Бристольского онкологического центра

Daniel. R, 2000. Living with Cancer, London, Robinson.

Sen, J, 1996. Healing Foods Cookbook, London, Thorsons, HarperCollins.

Название книги

Ваша жизнь в ваших руках. Как понять, победить и предотвратить рак груди и яичников

Плант Джейн

Библиография